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 I 
ABSTRACT 
The present study is part of HYPERGENES Project, focused on the 
definition of a comprehensive genetic-epidemiological model of complex 
traits like essential hypertension and of intermediate phenotypes related 
to hypertension. We specifically focused on the identification of genetic 
biomarkers related to Glomerular Filtration Rate (GFR) as index of renal 
function.  
Chronic kidney disease (CKD), defined as either kidney damage or 
decreased kidney function for 3 or more months (GFR < 60 ml/min per 
1.73m
2
)
 
affects about 6-11% of the general population. A strong 
relationship has been reported between renal dysfunction, hypertension 
and cardiovascular diseases; hypertension is present in more than 80% of 
patients with CKD and contributes to progression to end stage renal 
disease and to cardiovascular events as well. 
Apart from the risk conferred by traditional cardiovascular risk factors, 
eGFR has a strong genetic component. We therefore performed a 
genotype-phenotype association analysis in subjects affected by essential 
hypertension and in a population based cohort. The analyses have been 
carried on using: 1) 1,634 hypertensives from the HYPERGENES Discovery 
phase and 1,198 hypertensives from the HYPERGENES Validation phase; 
2) 2,697 subjects from Epogh-Flemengho population based sample 3) 
1,952 subjects from Epogh-Flemengho population based sample with GFR 
follow-up data, using the difference between the last and the first 
measurement as phenotype of renal function. 
Using a Genome wide association (GWA) approach, in the HYPERGENES 
Discovery sample we identified a potential novel variant associated with 
hypertension and renal function in STAC gene (rs4678878, p-value of 
3.83x10
-8
). This gene is likely involved in a neuron-specific signal 
transduction, although its function is not yet completely clear. This result 
was not validated in HYPERGENES Validation and in the population based 
studies. The finding needs further investigation performing a fine 
mapping of the region.  
Through a candidate gene approach, we could identify some variants, 
mapping in genes already known as associated to renal function (PPARA, 
CST3-CST9 region, PRKAG2, ABCA1, NEDD4L). 
The identification of genetic variants affecting renal function could help 
to better understand not only the GFR variability in the general 
population but also the pathophysiology of CKD and progressive kidney 
function decline. Ultimately, this could lead to novel tools for diagnosis, 
prevention and therapy of CKD. 
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Il presente studio fa parte del progetto HYPERGENES, che si pone come 
obiettivo la definizione di un modello genetico-epidemiologico di 
patologie a tratto complesso come l'ipertensione e di fenotipi intermedi 
ad essa correlati. In particolare lo scopo di questo lavoro è 
l'identificazione di biomarkers genetici correlati al tasso di filtrazione 
glomerulare (Glomerular Filtration Rate, GFR) come indice di funzionalità 
renale.  
L'insufficienza renale cronica (Chronic kidney disease, CKD), definita come 
danno renale o come diminuita funzionalità renale per 3 o più mesi (GFR 
< 60 ml/min per 1.73m
2
), colpisce il 6-11% della popolazione. Esiste uno 
stretto legame tra diminuita funzionalità renale, ipertensione e patologie 
cardiovascolari; l'ipertensione è presente in più dell'80% dei pazienti con 
CKD e contribuisce al progredire del danno renale sia in termini di 
insufficienza renale terminale che in termini di patologie cardiovascolari. 
Oltre ai tradizionali fattori di rischio cardiovascolari, l'eGFR ha una forte 
componente genetica. Abbiamo quindi analizzato l'associazione genotipo-
fenotipo in soggetti ipertesi e in uno studio di popolazione. Sono stati 
analizzati : 1) 1,634 pazienti ipertesi facenti parte della fase di Discovery 
del progetto HYPERGENES e 1,198 pazienti ipertesi della fase di Validation 
2) 2,697 soggetti apparteneti allo studio di popolazione Epogh-Flemengho 
3) 1,952 soggetti apparteneti allo studio di popolazione Epogh-Flemengho 
con dati di follow up per il fenotipo GFR, usando la differenza tra l'ultima 
e la prima misurazione come fenotipo di funzionalità renale. 
Usando un approccio Genome wide (GWA), nel campione di Discovery del 
progetto HYPERGENES abbiamo identificato una nuova variante 
potenzialmente associata con l'ipertensione e con la funzionalità renale 
nel gene STAC (rs4678878, p-value=3.83x10
-8
). Questo gene è 
presumibilmente coinvolto nella trasduzione neuronale, nonostante la 
sua funzione non sia ad oggi completamente chiarita. Questo risultato 
non è stato confermato nella Validation di HYPERGENES e negli studi di 
popolazione e sono necessarie ulteriori analisi eseguendo un fine 
mapping della regione. 
Utilizzando l’approccio gene candidato abbiamo identificato alcune 
varianti localizzate in geni tradizionalmente associati alla funzionalità 
renale (PPARA, regione CST3-CST9, PRKAG2, ABCA1, NEDD4L). 
L'identificazione di varianti genetiche che influenzano la funzionalità 
renale potrebbe essere utile per comprendere non solo la variabilità del 
GFR nella popolazione ma anche la patofisiologia della CKD e della 
diminuzione progressiva della funzionalità renale. Infine potrebbe aiutare 
a sviluppare nuovi metodi di diagnosi, prevenzione e terapia della CKD.  
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SYMBOLS 
 
BP: Blood Pressure 
CKD: Chronic Kidney Disease 
CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration  
CVD: Cardiovascular Disease 
D': D prime  
DBP: Diastolic Blood Pressure 
EH: Essential Hypertension 
eGFRcys: Glomerular Filtration rate estimated from cystatin C 
eGFRcrea: Glomerular Filtration rate estimated from serum creatinine 
eGFR: estimated Glomerular Filtration Rate 
FA: Fatty acid 
GFR: Glomerular Filtration Rate 
GWAs: Genome Wide Association Study 
LD: Linkage Disequilibrium 
MDRD: Modification of Diet in Renal Disease  
PCA: Principal Component Analysis 
r
2
: r squared 
SBP: Systolic Blood Pressure 
TOD: Target Organ Damage 
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1. INTRODUCTION 
1.1. Outline of Renal anatomy and physiology 
1.1.1. Renal Morphology 
Kidneys are organs that serve essential regulatory role in the urinary system and also 
serve homeostatic functions such as the regulation of electrolytes, maintenance of acid-
base balance, and regulation of blood pressure (via maintaining salt and water balance). 
They serve the body as a natural filter of the blood, and remove wastes, which are 
diverted to the urinary bladder. In producing urine, the kidneys excrete wastes such as 
urea and ammonium, and they are also responsible for the readsorption of water, 
glucose, and aminoacids. The kidneys also produce hormones including calcitriol, 
erythropoietin, and the enzyme renin. 
The basic unit of the kidney is the nephron. Each nephron consists of a glomerulus, a tuft 
of capillaries interposed between two arterioles (the afferent and efferent arterioles), and 
a series of tubules lined by a continuous layer of epithelial cells. The glomeruli are located 
in the outer part of the kidney, the cortex, whereas the tubules are presented in both the 
cortex and the medulla, the inner part of the kidney. 
The initial step in the excretory function of the nephron is the formation of an ultrafiltrate 
of plasma across the glomerulus. This fluid then passes through the tubules and is 
modified by reabsorption and by secretion. Fluid filtered across the glomerulus enters 
Bowman’s space and then the proximal tubule, composed by an initial convoluted 
segment and a later straight segment, the pars recta. The loop of Henle begins at the end 
of the pars recta and includes a thin descending limb and a thin and thick segment of the 
ascending limb. This hairpin configuration plays a major role in the excretion of a 
hyperosmotic urine. 
The thick ascending limb has a cortical segment that returns to the region of the parent 
glomerulus. In this area, where the tubule approaches the afferent glomerular arteriole, 
are located the specialized tubular cells of the macula densa. The juxtaglomerular cells of 
the afferent arteriole and the macula densa compose the justaglomerular apparatus, 
which plays a central role in renin secretion. 
After the macula densa, there are three cortical segments: the distal convoluted tubule, 
the connecting segment and the cortical connecting tubule. The connecting segments of 
many nephrons drain into a single collecting tubule. Fluid leaving the cortical collecting 
tubule flows into the medullary collecting tubule and drains sequentially into the calyces, 
the renal pelvis, the ureters, and the bladder. 
The segmental subdivision of the nephron is based upon different permeability and 
transport characteristics that translate in important differences in function [1]. 
1.1.2. Renal circulation and Glomerular Filtration Rate regulation 
Kidney has a blood flow of approximately 400 ml/100g of tissue per minute (20 percent of 
the cardiac output), much greater than that observed in other well perfused vascular beds 
such as heart, liver and brain.  
Bloods enters the kidney through the renal arteries and passes through serial branches 
(interlobar, arcuate, interlobular) before entering the glomeruli via the capillary wall. It 
then leaves the glomeruli via the efferent arterioles and enters the postglomerular 
capillaries. In the cortex, these capillaries run in apposition to the adjacent tubules, 
although not necessarily to the tubule segments from the same glomerulus. In addition, 
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branches from the efferent arterioles of the juxtamedullary glomeruli enter the medulla 
and form the vasa recta capillaries. Blood returns to the systemic circulation through 
veins similar to the arteries in name and location. 
The renal circulation affects urine formation in the following ways: 
1. The rate of glomerular filtration is an important determinant of solute and water 
excretion 
2. The peritubular capillaries in the cortex return reabsorbed solutes and water to 
the systemic circulation and modulate the degree of proximal reabsorption and 
secretion 
3. The vasa recta capillaries in the medulla return reabsorbed salt and water to the 
systemic circulation and participate in the countercurrent mechanism, permitting 
the conservation of water by the excretion of a hyperosmotic urine  
Systemic blood pressure has a crucial role in controlling kidney function. Since the rate of 
glomerular filtration is directly related to the hydrostatic blood pressure in glomerular 
capillaries, any increase in blood pressure results in a corresponding increase in filtration 
and urine output. Since this process ultimately decreases blood volume, the kidneys are a 
powerful mean of controlling long term blood pressure. Conversely, drops in blood 
pressure have the opposite effect. This mechanism is important because it illustrates how 
circulatory and renal systems interact as blood pressure changes affect kidney function 
and vice versa [2]. 
Glomerular Filtration Rate (GFR) describes the flow rate of filtered fluid through the 
kidney. It is normally maintained within relatively narrow limits to prevent inappropriate 
fluctuations in solute and water excretion. Regulation of the GFR is primarily achieved by 
alterations in arteriolar tone that influence both the hydraulic pressure in the glomerular 
capillary and renal blood flow. In normal subjects GFR is maintained by autoregulation, a 
phenomenon intrinsic to the kidney that allow GFR and plasma filtration rate to remain 
roughly constant over a wide range of arterial pressures through changes in afferent 
arteriolar resistance. Autoregulation is mediated by at least three factors: stretch 
receptors in the afferent arteriole, angiotensin II and tubuloglomerular feedback. 
 Strech receptors: myogenic stretch receptors in the wall of the afferent arteriole 
increase the degree of stretch and promote arteriolar constriction in response to 
an elevation in renal perfusion pressure.  
 Angiotensin II: The afferent arteriolae of each glomerulus contains specialized 
cells called juxtaglomerular cells. These cells synthesize the precursor prorenin, 
which is cleaved into the active proteolytic enzyme renin. Active renin is then 
stored in and released from secretory granules. More proximal cells in the 
interlobulary artery can also be recruited for renal release when the stimulus is 
prolonged. Renal hypoperfusion, produced by hypotension or volume depletion, 
and increased sympathetic activity are the major stimuli to renin secretion. Renin 
initiates a sequence of steps that begins with cleavage of a decapeptide 
angiotensin I from renin substrate (angiotensinogen), an alfa2-globulin produced 
in the liver (and other organs including the kidney). Angiotensin I is then 
converted into angiotensin II through a reaction catalyzed by the angiotensin 
converting enzyme (ACE), located in the lung, in the luminal membrane of 
vascular endothelial cells, the glomerulus itself and other organs. Angiotensin II 
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has two major systemic effects: systemic vasoconstriction (by arteriolar 
vasoconstriction and consequent elevation of systemic vascular resistance) and 
sodium and water retention. 
 Tubuloglomerular feedback (TGF) refers to the alterations in GFR that can be 
induced by changes in tubular flow rate. This phenomenon is mediated by 
specialized cells in the macula densa segment at the end of the cortical thick 
ascending limb of the loop of Henle; these cells sense changes in the delivery and 
subsequent reabsorption of chloride. An elevation in renal perfusion pressure 
can activate TGF via an initial rise in GFR; the ensuing increase in macula densa 
chloride delivery will then initiate a response that returns both GFR and macula 
densa flow toward normal. 
In hypovolemic states these responses can be overridden by neurohumoral 
vasoconstriction, in an attempt to maximize coronary and cerebral perfusion, mainly 
through a marked stimulation of the vasocostrictor sympathetic nervous and renin-
angiotensin systems. Norepinephrine directly increases the afferent tone and indirectly 
enhances efferent resistance via activation of the release of renin and angiotensin II. 
Angiotensin II and norepinephrine also stimulate glomerular prostaglandin production, 
which plays an important role in modifying vasocostrictive effects.  
A major function of autoregulation and TGF is preventing excessive salt and water losses. 
Endothelin, released locally from endothelial cells, is another important renal 
vasoconstrictor that affects both afferent and efferent glomerular arterioles, leading to 
reductions in renal blood flow and GFR. This is not an important regulator of renal 
hemodynamics in normal subjects but plays a major role in subjects with posthischemic 
acute renal failure. Another vasoactive factor released from the endothelial cells is nitric 
oxide, lowering renal vascular resistance. 
In contrast volume expansion tends to be associated with increased renal perfusion and a 
mild rise in GFR. Reduced secretion of angiotensin II and norepinephrine and enhanced 
release of dopamine and atrial natriuretic peptide contribute to this response: 
 Dopamine dilates both the afferent and the efferent arterioles, raising renal 
blood flow while producing a lesser increment or no change in GFR 
 Atrial natriuretic peptide determines afferent dilation and efferent constriction, 
causing a raise in the pressure of the glomerular capillaries and therefore in GFR 
These hormonal alterations also facilitate excretion of the excess of sodium. 
1.2. Estimation of Glomerular Filtration Rate  
GFR is considered the best index of the level of kidney function. The normal level of GFR 
varies according to age, sex, and body size. Normal GFR in young adults is approximately 
120 to 130 ml/min per 1.73 m
2
 and declines with age.  
The gold standard markers for GFR extimation have the characteristic of being completely 
filtered by the glomerulus and not reabsorbed along the tubule. Exogenous substances 
like inulin, iothalamate, diethylenetriaminepentaacetic acid and iohexol fulfill these 
characteristics. However they aren’t commonly used in clinical practice because they 
require invasive, expensive and time-consuming procedures. 
Serum creatinine concentration is currently used to assess kidney function: creatinine is 
derived from the metabolism of creatine in skeletal muscle and it is released into the 
plasma at a relatively constant rate. Plasma creatinine concentration is therefore very 
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stable, varying less than 10 percent per day in serial observations in normal subjects [1]. 
Like inulin and the exogenous markers mentioned above, it is freely filtered across the 
glomerulus and is neither reabsorbed nor metabolized by the kidney. However creatinine 
is secreted at a low extent in the tubule via the organic cation secretory pump in the 
proximal tubule, resulting in creatinine excretion exceeding the amount filtered by 10 to 
20 percent.  
The use of serum creatinine per se as an index of kidney function is by the way 
confounding, as it can be influenced by several factors, including different skeletal muscle 
masses, individual age, sex and race [3]. At birth it reflects the maternal serum creatinine 
level, it rapidly decrease during the first month of life to about 0.25 mg/dL and then 
gradually increases with age until adolescence, where further growth and development of 
muscle mass results in different constant values for men and women. Finally, at older 
ages, serum creatinine slightly goes up again (figure 1)[4]. Concerning race, African-
American men have higher values, on average, than Caucasian males, mainly because they 
have more muscle mass. 
 
 
Figure 1: Expected time-evolution of serum creatinine concentration in healthy  
Caucasian [4]. 
A further critical point in using serum creatinine data is the calibration of laboratory 
serum creatinine assay, which can vary across laboratories. The National Health and 
Nutrition Examination Surveys (NHANES), one of the most important sources of data 
about the prevalence of chronic diseases and health conditions, including kidney function, 
in the US population, broadly analyzed this calibration bias in most routine serum 
creatinine measurement procedures. They could validate a serum creatinine calibration 
procedure in order to compare serum creatinine measurement in the NHANES III (1988-
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1994) and NHANES 1999-2000, 2001-2002, and 2003-2004 surveys to standard creatinine 
by using an assay traceable to known gold-standard reference methods (National Institute 
of Standards and Technology) [3,5].  
1.2.1. Impact of age on GFR 
The ideal all-purpose GFR prediction equation probably does not exist, as GFR changes 
during life and the major determining factor in all eGFR-equations, serum creatinine, 
changes also during life, but in a completely different way. With particular reference to 
children, the normal level of GFR varies with age, and consequently with body size, and 
increases with maturation from infancy, approaching adult mean values at approximately 
2 years of age. It remains constant during growth from child to adult and then gradually 
starts to decline with age [4]. GFR declines with normal ageing usually begin after 30–40 
years of age. The rate of decline may accelerate after 50–60 years of age. This decline 
appears to be a part of the normal physiologic process of cellular and organ senescence 
and is associated with structural changes in the kidneys [6]. 
 
 
Figure 2: Expected time-evolution of GFR in healthy Caucasian [4].
 
 
Verhave et al. [7] reported a study on 8,446 subjects where measured creatinine 
clearance showed a parabolic curve over age with an acceleration of clearance decline 
above 50 years in both males and females. Grewal et al. reported their experience in 428 
kidney donors evaluated with radioactive chromium EDTA. GFR remained constant until 
the age of 40 years and then declined at a rate of 9.1 ml/min/1.73m
2
 per decade. In 
agreement with these studies, Douville et al. reported a relative stable GFR up to the age 
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of 30, followed by a slow decline [8]. In particular they showed a regular decrease of GFR 
from ~120 ml/min/1.73m
2
 in early adulthood down to ~60 ml/min/1.73m
2
 in the 80s with 
a continuous trend over 50 years [9]. 
1.2.2. eGFR equations in adults 
Several equations have therefore been developed to predict creatinine clearance using 
serum creatinine together with patient’s anthropometric data. The predictions given by 
these equations represent an approximated estimate of true GFR.  In adults the most 
commonly used formulas are: 
1. The Cockcroft-Gault equation 
2. The Modification of Diet in Renal Disease (MDRD) equation 
3. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation 
The three equations are reported in details in table 1 [10, 11]. 
 
Cockcroft-Gault equation for estimated GFR in ml/min 
Men (140-age × weight) / (72 × serum creatinine) 
Women (140-age × weight) / (72 × serum creatinine) × (0.85) 
Where age is in years, weight in kg and serum creatinine in mg/100 ml 
Correction factor for ethnicity: none 
Four-variable MDRD Study equation for estimated GFR in ml/min per 1.73 m2 
Men (186* x serum creatinine
-1.154
 x age
-0.203
) 
Women (186* x serum creatinine
-1.154
 x age
-0.203
) x (0.742) 
Where serum creatinine is measured in mg/100 ml and age in years. 
Correction factor for ethnicity: if black, GFR estimates must be multiplied by 1.210 
CKD-EPI equation 
Men   
serum creatinine ≤0.9 mg dL 141
α x
 (serum creatinine/0.9)
-0.411
 x (0.993)
 age
 
serum creatinine >0.9 mg/dL 141
α x 
(serum creatinine/0.9)
-1.209
 x (0.993)
 age
 
Women   
serum creatinine ≤0.7 mg/dL 144
α x
 (serum creatinine/0.7)
 -0.329
 x (0.993)
 age
 
serum creatinine >0.7 mg/dL 144
α x
 (serum creatinine/0.7)
 -1.209
 x (0.993)
 age
 
Where serum creatinine is measured in in mg/100 ml and age in years 
Correction factor for ethnicity: if black, the coefficient α is 163 in men and 166 in 
women 
CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration; GFR = glomerular 
filtration rate;  
MDRD = Modification of Diet in Renal Disease. 
*186 must be replaced with 175 when creatinine measurements are standardized 
with reference material from the National Institute of Standards and Technology. 
Table 1: eGFR equations in adults. 
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The Cockcroft-Gault equation tends to overestimate creatinine clearance in edematous or 
obese people.  
The MDRD equation has gained widespread acceptance and is reported by most clinical 
laboratories. The MDRD study equation has also been widely used to assess the burden of 
chronic kidney disease in many epidemiologic studies, including the CKD-Gen consortium 
study, a large, still ongoing, meta-analysis of genome-wide association data in 67,093 
Caucasian individuals from 20 population based studies to identify new susceptibility loci 
for reduced renal function, estimated by serum creatinine (eGFRcrea), cystatin C 
(eGFRcys), and Chronic Kidney Disease incidence [12, 13]. As MDRD Study equation was 
developed in people with chronic kidney disease (CKD), it’s not accurate (underestimates) 
in estimating GFR values greater than 60 ml/min/1.73 m
2
.  
The CKD_EPI equation was recently developed and validated [12] and showed to have 
better performance than the MDRD equation, especially at higher GFR values. 
We chose to use the MDRD formula, despite it's probably less accurate at higher GFR 
values, as this formula is currently widely used and allowed us to compare our results with 
published data. 
1.2.3. eGFR equation in children 
Accurate estimation of kidney function in children is important from a clinical, research, 
and public health perspective and given the wide range of maturation of skeletal muscle 
and growth observed in the pediatric population, recognition of abnormal creatinine 
values is challenging [14]. 
The Schwartz formula, devised for children in the mid-1970s, estimates GFR from an 
equation that uses serum creatinine, height, and an empirical constant. GFR as estimated 
by the Schwartz formula has been used as one of the enrollment criteria for the Chronic 
Kidney Disease in Children (CKiD) study, a National Institutes of Health–funded North 
American cohort study whose goal is to recruit children and adolescents with mild to 
moderate CKD and characterize progression and effects of CKD on cardiovascular, growth, 
and behavioral indices [15, 16]. The equation is reported in table 2. 
 
Schwartz equation for estimated GFR in ml/min 
Children and adolescent girls (0.55 × height) / serum creatinine 
 
Adolescent boys (≥ 13 years) (0.7 × height) / (serum creatinine)  
Where age is in years, height in m and serum creatinine in mg/100 ml 
Table 2: eGFR equation in children and adolescent. 
 
1.3. Chronic Kidney Disease 
Chronic kidney disease affects about 6-11 % of the general population. It is defined as 
either kidney damage or decreased kidney function (decreased GFR) for 3 or more 
months. Kidney disease can be diagnosed without knowledge of its cause and kidney 
damages are usually ascertained by markers rather than by kidney biopsy. Proteinuria is 
the principal marker of kidney damage, together with the albumin-creatinine ratio. An 
albumin–creatinine ratio greater than 17 mg/g in men and greater than 25 mg/g in 
  8 
women is considered abnormal. Other markers of damage include abnormalities in urine 
sediment, abnormalities in blood and urine chemistry measurements, and abnormal 
findings on imaging studies. Persons with normal GFR but with markers of kidney damage 
are at increased risk for adverse outcomes of chronic kidney disease.  
A GFR level less than 60 ml/min per 1.73 m
2
 represents loss of half or more of the adult 
level of normal kidney function. Below this level, the prevalence of complications of 
chronic kidney disease increases. Because GFR declines with age, the prevalence of 
chronic kidney disease increases with age; approximately 17% of persons older than 60 
years of age have an estimated GFR less than 60 ml/min per 1.73 m
2
.  
Nowadays CKD is a common condition, continuously increasing in prevalence. Due to its 
impact on quality of life, cardiovascular disease (CVD) incidence, and mortality, it is an 
important public health challenge [17]. 
Despite its increasing prevalence, our understanding of the underlying risk factors and 
pathophysiologic mechanisms remains incomplete. Obesity, smoking, hypertension, high 
cholesterol, and diabetes are key risk factors for CKD. However, additional underlying 
factors contribute to its etiology. In particular, studies have consistently demonstrated 
important genetic contributions to the disease onset [13].  
Identification of biomarkers that allow early identification of CKD patients at high risk of 
progression would be useful for early and targeted treatment to improve patient care 
[18]. 
1.3.1. CKD Classification 
Data from the Third National Health and Nutrition Examination Survey (NHANES III) show 
the increasing prevalence of complications of chronic kidney disease at lower levels of 
GFR. This provide a strong basis for using GFR to classify the stage of severity of chronic 
kidney disease. Table 3 shows the classification of stages of chronic kidney disease 
estimated using data from NHANES III [19, 20].  
 
Stage Description GFR, ml/min per 1.73 m
2
 
1 Kidney damage with normal or increased GFR  90 
2 Kidney damage with mildly decreased GFR 60 to 89 
3 Moderately decreased GFR 30 to 59 
4 Severely decreased GFR 15 to 29 
5 Kidney failure < 15 or dialysis 
Table 3: Stages of CKD. 
1.4. Renal Dysfunction and Hypertension 
A strong relationship has been reported between renal dysfunction, hypertension and 
cardiovascular diseases. Structural and functional cardiac abnormalities have been 
demonstrated in subjects with mild renal function impairment. Cardiovascular disease is a 
frequent complication of renal failure and is the most common cause of death in patients 
with CKD. Kidney dysfunction and loss of blood pressure control have a reciprocal crucial 
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role in the pathophysiology of hypertension: renal disease could be either a cause or an 
effect of hypertension. It is epidemiologically more common to see renal failure leading 
on to hypertension, but the converse is controversial [19, 21]. 
Glomerular vessels regulate the blood flow by vasoconstriction or vasodilatation 
depending on the perfusion pressure, to keep the perfusion at the glomerulus constant. 
Prolonged high perfusion pressures can lead to significant vasoconstriction, which can 
then cause localized damage to the glomeruli. This can cause necrosis of the glomeruli 
leading to microalbuminuria, which could lead to significant proteinuria if the disease is 
not treated. Renal failure could also be an effect of atherosclerosis affecting the renal 
arteries, leading to under-perfusion [21].  
Hypertension also plays a major role in cardiac damage in CKD via left ventricular 
hypertrophy induction. In addition, a reduction in coronary reserve and capillary density 
that occurs in CKD patients exposes them to coronary ischemia, which in turn leads to 
worsening of ventricular dysfunction [19, 22].  
Several mechanisms are involved in the strong inter-relationship between hypertension 
and renal failure, including the renin-angiotensin system, the sympathetic nervous system 
activation and the endothelial dysfunction. 
Renin-angiotensin System 
Sodium retention and activation of the renin-angiotensin system have been considered 
the most important mechanisms involved in the elevation of blood pressure in subjects 
with kidney disease.   
Angiotensin II is a vaso-active peptide that causes blood vessels to constrict, resulting in 
increased blood pressure. Angiotensin II also stimulates the secretion of the hormone 
aldosterone from the adrenal cortex. Aldosterone causes the tubules of the kidneys to 
increase the reabsorption of sodium and water into the blood. This increases the volume 
of fluid in the body, which also increases blood pressure. If the renin–angiotensin–
aldosterone system is too active, blood pressure will be too high [22].  
Sympathetic nervous system activation  
In kidney failure plasma catecholamine concentration is elevated and increased nerve 
sympathetic traffic has been demonstrated.  
There is clear evidence that Angiotensin II enhances sympathetic activity, both at 
peripheral and central sites. It stimulates the muscle sympathetic nerve activity (MSNA), 
which indicates central sympathetic activation and enhances norepinephrine release 
through a presynaptic effect. Sympathetic activation results in further activation of the 
renin-angiotensin system.  
Furthermore during renal ischemia adenosine is released. Adenosine evokes an increase 
in afferent renal nerve traffic. 
Basal activity of central sympathetic activity is inhibited by central nitric oxide production. 
Inhibition of nitric oxide synthesis results in an increase of central sympathetic activity. 
Experimental studies further suggest that stimulation of the central sympathetic nervous 
system activity by renal afferent impulses may be mediated by local activation of 
Angiotensin II, which stimulates central sympathetic outflow by inhibition of NOSmRNA 
abundance [22].  
Renalase, a new regulator of cardiac function and blood pressure produced by the kidney 
has been recently identified. Renalase metabolizes catecholamines (dopamine-
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epinephrine-norepinephrine) and is secreted into plasma and urine of healthy persons 
(not in uremic individuals). To what extent the impairment of renalase production 
contributes to sympathetic hyperactivity and blood pressure elevation in CKD remains to 
be established [22]. 
Endothelial dysfunction  
Endothelial dysfunction and remodeling of blood vessels may participate not only in 
vascular complications in patients with kidney disease but also in the maintenance of 
elevated blood pressure.  
Hypertension, together with dyslipidemia and diabetes, are considered major risk factors 
for the development of endothelial dysfunction and progression of atherosclerosis. 
Inflammatory mediators and activation of the renin-angiotensin system contribute, 
through enhanced production of reactive oxygen species, to atherogenesis in CKD [23].  
Endothelins are powerful vasoconstrictor peptides that also play numerous other 
functions in many different organs. Endothelin-1 (ET-1) is the most abundant and 
important of this family of peptides in blood vessels. ET-1 is involved in renal and cardiac 
target organ damage in hypertension. Production of ET-1 is increased in the endothelium 
and the kidney in salt-dependent models of hypertension. It induces an inflammatory 
response by increasing oxidant stress in the vascular wall, which leads to vascular 
remodeling and endothelial dysfunction. ET-1 production is increased by salt loading, 
which by activation of renal ETB receptors inhibits sodium reabsorption. ET-1 acts by 
stimulating ETA and ETB receptors. Both ETA and ETB receptors are localized on vascular 
smooth muscle cells where they induce their vasoconstrictor, proliferative and 
hypertrophic action. ETA receptors are the predominant ET vasoconstrictor receptors in 
arteries. Vasoconstrictor ETB receptors are present in the veins and pulmonary vessels in 
larger numbers than in arteries, although ETA still predominate over ETB receptors in 
these vessels. ETB receptors are also localized on endothelial cells and act through the 
production of NO and prostacyclin to exert a vasodilator effect. The endothelin system 
has been demonstrated to participate patho-physiologically in numerous conditions, 
including hypertension and renal failure [24]. 
1.5. Genome Wide Association Study 
A genome-wide association study (GWAS) is a powerful hypothesis-free approach to 
unravel the genetic component by association analyses of CKD with several million genetic 
variants distributed across the genome. The aim of an association study is to map genetic 
loci associated to a complex phenotype by comparing the genetic variations between 
individuals with the disease (cases) and without the disease (controls), in order to identify 
allelic variants that are enriched among sufferers of the disease. The phenotype used in 
genome-wide association studies can be either qualitative (disease yes or no) or 
quantitative [25].  
Mapping genetic loci with GWAS is based on Linkage Disequilibrium (LD), which is defined 
as a condition in which some combinations of alleles or genetic markers occur more or 
less frequently than can be accounted by chance. LD indicates that the two alleles rely on 
the same DNA strand and are transmitted together [26]. 
Linear (for continuous traits, e.g. eGFR) and logistic (for dichotomous traits, e.g. CKD) 
regression models are used to calculate the mean shift in the distribution (for quantitative 
traits) or in the disease probability (for dichotomous phenotypes) per risk allele 
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(compared to the other, the reference allele).  
With respect to the candidate genes approach, the genome wide association studies allow 
to identify new chromosomal regions containing disease-susceptibility loci by detecting 
differences in allele frequencies between cases and controls. Association analysis is a 
good choice of methodology to look for genetic factors implicated in complex diseases but 
we must be careful with the many factors that can lead to false-positive or false-negative 
results: issues related to sample size, power, genetic effect sizes, replication and 
population stratification must be taken into account when planning an association study 
of any complex disease.  
GWAS do not provide data on all genetic variability but only low risk-common alleles (i.e 
those that are represented in more than 1-5% of the population) with large effects are 
identified: GWAS identify loci and not genes and cannot easily identify loci at which there 
are many rare allele in any given population. This approach is designed to find loci that fit 
the common disease-common variant hypothesis of human disease and such variants are 
not sufficiently frequent to be captured by current GWA genotyping arrays [27].  
Since the publication of the first GWAS in 2005, this method has led to the discovery of 
novel loci for numerous human common diseases and phenotypes. The GWAS approach 
has been fostered by the publication of the human genome just over ten years ago [28, 
29], by the identification of millions of single nucleotide polymorphisms across 
populations from the “International HapMap Project” (International HapMap Consortium, 
2005), by the knowledge that subsets of these SNPs can capture common genetic 
variations via linkage disequilibrium and by advances in the microarray-based technology. 
With the high-throughput genotyping technologies offered by companies such as 
“Illumina” and “Affymetrix”, it is now possible to rapidly genotype more than one million 
SNPs across the whole genome per person in a single analytical process.  
1.6. State of the art on genetic loci found associated with eGFR 
Multiple studies such as familial studies have provided evidence for a genetic component 
to kidney disease. Heritability estimates of eGFR are reported between 0.41 and 0.75 in 
individuals with the major CKD risk factors hypertension or diabetes, and as 0.33 in a 
population-based sample [30].  
The first large GWAS Consortium (CHARGE)
 
[30] identified susceptibility variants for renal 
function and CKD at the UMOD, SHROOM3, and STC1 loci in nearly 20,000 individuals. By 
the way, together, single nucleotide polymorphisms (SNPs) at these loci, explain only 
0.43% of the variance in eGFR, suggesting that additional loci remained to be identified. 
The CKDGen Consortium realized a huge meta-analysis in up to 130,600 European 
ancestry participants belonging to 25 different cohorts for the discovery study and 17 
different cohorts for the replication study. They analyzed renal function using three 
different phenotypes: eGFR evaluated from serum creatinine, eGFR evaluated from serum 
cystatin c and CKD, defined as eGFRcrea < 60 ml/min/1.73m
2
.  Using eGFR estimate from 
serum cystatin allows discriminating genetic variants truly related to kidney function from 
those related to serum concentrations of the estimation marker and creatinine 
metabolism.  
Kottgen et al (2010) identified 20 new loci associated with eGFR and CKD. Of these, 13 are 
likely to be involved in renal function and in susceptibility to CKD (in or near LASS2, GCKR, 
NAT8/ALMS1, TFDP2, DAB2, SLC34A1, VEGFA, PRKAG2, FAM122A/PIP5K1B, ATXN2, 
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DACH1, UBE2Q2/FBXO22, and SLC7A9), whereas 7 are likely to be associated with 
creatinine production or secretion (CPS1, SLC22A2, TMEM60, WDR37, SLC6A13, WDR72, 
and TBX2/BCAS3) [19].  
SNPs in the GATM and CST3 gene regions have been associated repeatedly with GFR. 
Variants in the GATM gene, involved in creatine synthesis are associated with GFR 
estimated from serum creatinine [13, 19, 31].  
The UMOD risk variant, that shows association with GFR estimated from serum creatinine 
and with GFR estimated from serum cystatin C, likely is related to true GFR [31].   
The CKD-Gen Consortium further investigated association with 16 genetic marker loci 
previously identified as associated to kidney function and prevalent CKD evaluating the 
relevance of these SNPs to the initial development of CKD or to ESRD risk. Of the 16 SNPs 
analyzed, 11 showed association with incident CKD: SNPs in UMOD, PRKAG2, ANXA9, 
DAB2, SHROOM3, DACH1, STC1, SLC34A1, ALMS1/NAT8, UBE2Q2 and GCKR showed p-
values ranging from p = 4.161029 in UMOD to p = 0.03 in GCKR. The odds ratios (OR) for 
incident CKD of the minor alleles at each of the 11 loci ranged from 0.76 per copy of the T 
allele (allele frequency 18%) at the UMOD locus to 1.19 per copy of the A allele (allele 
frequency 22%) at PRKAG2. After additional adjustment for baseline eGFR, 6 SNPs (at the 
UMOD, PRKAG2, ANXA9, DAB2, DACH1 and STC1 loci) remained significantly associated 
with incident CKD, with minimal attenuation of effect size. Only two SNPs showed 
nominally significant associations with ESRD: rs1260326 in GCKR (OR= 0.93; p-value=0.03) 
and rs12917707 in UMOD (OR = 0.92; p-value = 0.04). From a functional point of view, the 
genes identified in this study were involved in calcium and phosphate homeostasis (STC1), 
the production of Tamm-Horsfall protein (UMOD), epithelial cell shape regulation 
(SHROOM3), nephrogenesis (ALMS1, VEGFA, potentially also DACH1), glomerular filtration 
barrier integrity and podocyte function DAB2, VEGFA), angiogenesis (VEGFA), metabolic 
kidney function (PRKAG2, potentially CKR, LASS2), ciliary function (ALMS1, GCKR-IFT172) 
and solute transport (SLC7A9, SLC34A1). 
Pattaro and collegues (2012) then identified 6 new loci in association with eGFR in or near 
MPPED2 (rs3925584), DDX1 (rs6431731), SLC47A1 (rs2453580), CKD12 (rs11078903), 
CASP9 (rs12124078) and INO80 (rs2928148). Significant associations between SNPs in 
SLC22A2 and eGFR were also identified in previous GWAS performed by the CKDGen 
Consortium [13, 32]. Differential expression of CDK12 (Cyclin-dependent kinase 12) 
inhibitors have been described in human glomerular disease. The CASP9 (caspase-9) gene 
encodes the third apoptotic activation factor that is involved in the activation of cell 
apoptosis, necrosis and inflammation. In the kidney, caspase-9 may play an important role 
in the medulla response to hyperosmotic stress and in cadmium-induced toxicity. For the 
remaining variants no previous link with renal function are reported [32].  
Böger et al. (2011) analyzed the association of markers with the initiation of CKD in more 
than 26,000 individuals from the general population using serial estimations of kidney 
function, and with ESRD in four case-control studies in subjects of European ancestry 
(3,775 cases, 4,577 controls) [33].  
Chambers et al. (2010) identified common variants at 2p12–p13, 6q26, 17q23 and 19q13 
associated with serum creatinine, marker of kidney function. Of these, rs10206899 (near 
NAT8, 2p12–p13) and rs4805834 (near SLC7A9, 19q13) were also associated with CKD 
[34].  
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Wang et al. (2001) demonstrated that the incidence of hypertension is influenced by 
genes encoding the angiotensin-converting enzyme (ACE; insertion/deletion [I/D]) 
polymorphism, alfa-adducin (Gly460Trp), and aldosterone synthase (344C/T). By 
interfering with blood pressure or sodium homeostasis, these genetic polymorphisms also 
may change renal function. They therefore investigated serum creatinine level, calculated 
and measured creatinine clearances, and 24-hour urinary protein excretion in subjects 
previously genotyped for these three polymorphisms and found that renal function was 
slightly but consistently impaired when both the ACE D and alfa-adducin Trp alleles were 
present, while the aldosterone synthase T allele did not strengthen genetic associations 
with the ACE D allele considered alone or in combination with the alfa-adducin Trp allele 
[35]. 
The Framingham Heart Study investigated possible association with GFR as marker of 
kidney function testing about 1,000 participants for 70,980 SNPs and identified as best 
hits rs2839235 (p-value = 1.6x10
-5
) using the GEE  (generalized estimating equation) 
method and rs6434804 using the FBAT (family-based association test) method (p-value = 
2.4x10
-5
) [36].  
1.7. Project Background: The HYPERGENES EUROPEAN PROJECT 
Data presented in this thesis are part of data generated within the HYPERGENES Project, 
an EU supported IP, under FP7 (http://www.HYPERGENES.eu), aimed at the definition of a 
comprehensive genetic- epidemiological model of essential hypertension and of the 
intermediate phenotypes of hypertension, specifically associated Target Organ Damage 
(TOD). 
The HYPERGENES Project investigated associations between genetic variants and EH 
pursuing a two- stage study by recruiting cases and controls from extensively 
characterized cohorts recruited over many years in different European regions 
Continental Italy, Sardinia and North Europe. 
The discovery phase consisted of 1,865 cases and 1,750 controls genotyped with the 1 
Million SNPs Illumina array. Best hits were followed up in a validation panel of 1,385 
additional cases and 1,595 controls that were genotyped with a custom array of 14,055 
SNPs. A new hypertension susceptibility locus was identified, localized in the promoter 
region of endothelial Nitric Oxide Synthase (eNOS) gene (rs3918226) showing strong 
association with EH (combined p-value = 2.58x10
-13
, OR = 1.54, 95% CI 1.37-1.73). This 
finding was further validated with a meta-analysis, using other in-silico/de novo 
genotyping data for a total of 21,714 subjects. Meta-analysis' results showed an overall 
OR of 1.34 (95% CI 1.25-1.44, p-value of 1.032x10
-14
). A quantitative analysis on a sample 
of 1,820 population-based individuals was then performed and revealed an effect size of 
1.91 (95% CI 0.16-3.66) for systolic BP and 1.40 (95% CI 0.25-2.55) for diastolic BP. A 
potential binding site for transcription-factors of ETS family directly next to rs3918226 was 
identified in-silico, suggesting a potential modulation of eNOS expression. The impact of 
rs3918226 on hypertension was further validated in a Longitudinal cohort study. The 
incidence of hypertension was investigated in relation to eNOS rs3918226 genotypes and 
their association with longitudinal changes in systolic and diastolic blood pressure in 
EPOGH (European Project on Genes in Hypertension) and FLEMENGHO (Flemish Study on 
Environment, Genes, and Health Outcomes) cohorts [37].  
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This last part of the project focuses on the association between hypertension and 
estimated Glomerular Filtration Rate (eGFR), a target parameter to evaluate kidney 
function damages and on the identification of biomarkers related to eGFR in a population 
based study. 
  15 
2. AIM OF THE STUDY 
The aim of the present work is to identify genetic markers of GFR in hypertensive subjects 
and in a population based study that includes a Cross sectional and a Longitudinal study. 
The analyses have been carried on using three different approaches:  
 Study 1: A genotype-phenotype association with eGFR as 
quantitative phenotype in two groups of hypertensives: 1,634 
individuals from the Discovery phase and 1,198 subjects from the 
Validation phase of HYPERGENES. 
 Study 2: An association analysis between SNPs and baseline eGFR in 
the Epogh-Flemengho population based sample (n=2,697).  
 Study 3: An association analysis between SNPs and Longitudinal 
changes in eGFR in subjects described at point 2 that have been 
followed for up to 23 years (n=1,952). 
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3. MATERIAL AND METHODS 
3.1. Sample Description 
3.1.1. HYPERGENES hypertensive samples 
This sample included hypertensives recruited during the Discovery and Validation phases 
of the HYPERGENES project for which eGFR phenotype was available. Subjects belong to 
three different geographic areas: North Europe, Continental Italy and Sardinia. 
Participants were included in the study as hypertensives if they could self report to be of 
Caucasian origin, were unrelated with other participants, had diastolic blood pressure 
(DBP)>90 mmHg and systolic blood pressure (SPB)>140 mmHg or were under 
antihypertensive treatment before the age of 50. 
We studied 1,634 hypertensive subjects of HYPERGENES Discovery phase genotyped for 
1,111,731 SNPs. In order to validate the results of this study, we performed a meta-
analysis with the CKDGen Consortium results. The meta-analysis was performed only for 
the SNPs that in both dataset showed a p-value ≤ 10
-3
. The CKDGen sample included 
74,354 subjects analyzed for renal function using eGFR evaluated from serum creatinine, 
eGFR evaluated from serum cystatin c and also defining chronic kidney disease based on 
eGFRcrea<60 ml/min. eGFR based on serum cystatin allows to discriminate true 
susceptibility loci for renal function from those related to creatinine production and 
secretion [14, 32].  
We also studied 1,198 cases from the Validation phase genotyped for 14,055 SNPs 
(custom chip). 
3.1.2. Population Based Sample 
The population based sample was recruited during several years for the Epogh-Flemengho 
study. It included 2,697 individuals, from 10 to 83 years old, with eGFR measurement 
available. From the overall sample, 1,952 subjects had multiple follow up measurements 
for eGFR. In the population based sample we performed a genotype-phenotype 
association in:  
1. A Cross sectional analysis on 2,697 individuals using baseline eGFR as 
quantitative phenotype. 
2.  A Longitudinal analysis in a subset of the Cross sectional sample composed by 
1,952 subjects with multiple eGFR measurements. We calculated delta eGFR as 
the difference between the last and the first measurement available for every 
subject.
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3.2. Cohorts contributing to the Study 
Table 4 summarizes the cohorts used during the different stages of the analysis. Each 
cohort is then described in detail below. 
 
Cohort 
Hypergenes 
Discovery 
Hypergenes 
Validation 
Population 
based Cross 
sectional 
Population based 
Longitudinal 
EPOGH-
FLEMENGHO 
X X X X 
Milano and 
Sassari 
X X   
Immidiet X    
WHSS X    
Paris  X   
Progress  X   
Table 4: Cohorts involved in the different stages of the analysis. 
 
 The FLEMENGHO (Flemish Study on Environment, Genes and Health Outcomes) - 
EPOGH (European Project on Genes in Hypertension) cohort has been the first 
large-scale study on genetic epidemiology of blood pressure and associated 
phenotypes in Europe and has already produced 35 scientific papers. It recruited 
family-based random samples in 5 eastern and 2 western European countries 
[38, 39]. Subjects were followed up to 23 years. According to the HYPERGENES 
"macro-region concept", the FLEMENGHO-EPOGH cohort is considered a "North-
European" cohort. In the Hypergenes project, from this cohort, 186 cases with 
eGFR data available were analyzed in the discovery phase while 43 hypertensives 
were used in the Validation analysis. For the Population Based study we could 
analyze 2,697 subjects in the Cross sectional analysis on eGFR. As 1,951 subjects 
also had multiple follow up measurement available, we analyzed them in the 
Longitudinal study on delta eGFR. 
 Milano and Sassari cohorts (Italian and Sardinian cohorts) have been collected 
with a focus on the pathophysiology of essential hypertension and TOD. In most 
hypertensives phenotypes were collected before any pharmacological treatment 
was started [40, 41].  
Overall the Italian cohort available for HYPERGENES includes 514 hypertensives 
with eGFR data available in the Discovery phase and 238 in the Validation phase. 
Sardinian cohort includes 704 hypertensives with eGFR available in the Discovery 
phase and 372 in the Validation phase. 
 The IMMIDIET study is a population-based Cross sectional study, funded by the 
European Union (FP5) [42]. It compares healthy couples from regions of England, 
Belgium and Italy in order to evaluate the present dietary habits and the risk 
profile of the three communities at different risk of myocardial infarction. A large 
body of clinical (mostly cardiovascular) and environmental data is available. In 
the HYPERGENES discovery phase we analyzed 158 cases with eGFR data 
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available. 
 The cohort of the Wandsworth Heart & Stroke Study (WHSS) [43] has the 
characteristic of being a multiethnic community-based study, drawn from the 
same geographical area of South London. The sample totals 1,577 individuals 
(~40% hypertensives), evenly distributed for ethnic origin; 33% Caucasians, 33% 
of African descent, 33% of South Asian descent. The population has been 
extensively phenotyped. Mortality follow-up through death certificates and 
cancer registrations are available. It is a unique multiethnic cohort sharing the 
same urban environment. 72 cases of Caucasian origin and with eGFR phenotype 
available were included in the Discovery phase. 
 Paris (France): The French hypertensive patients were selected from the 
HYPERGENES dataset of hypertensive families consecutively recruited in Paris, 
since 1990 [44]. The dataset comprises more than 1,000. In this study, 447 
hypertensives had eGFR phenotype available for the Validation analysis. 
 PROGRESS cohort. The “Perindopril protection against recurrent stroke study” 
(PROGRESS) was designed to determine the effects of a blood-pressure-lowering 
regimen in hypertensive and non- hypertensive patients with a history of stroke 
or transient ischemic attack [45]. 113 affected subjects had eGFR measurement 
available and were used for the Validation analysis. 
3.3. Phenotype 
The quantitative phenotype was eGFR calculated using the MDRD equation for adults and 
using the Schwartz formula for children (table 5). 
 
Four-variable MDRD Study equation for estimated GFR in ml/min per 1.73 m
2
 
Men (186 x serum creatinine
-1.154
 x age
-0.203
) 
Women (186 x serum creatinine
-1.154
 x age
-0.203
) x (0.742) 
Where serum creatinine is measured in mg/100 mL and age in years. 
Correction factor for ethnicity: if black, GFR estimates must be multiplied by 1.210 
Schwartz equation for estimated GFR in ml/min 
Children and adolescent girls (0.55 × height) / serum creatinine 
 
Adolescent boys (≥ 13 years) (0.7 × height) / (serum creatinine)  
Where age is in years, height in m and serum creatinine in mg/100 mL 
Table 5: MDRD and Schwartz equation. 
 
In the Longitudinal study we used delta eGFR, calculated as the difference between the 
first and the last measurement available in each patient. 
3.4. Genotyping and data filtering  
3.4.1. Genotyping and data filtering in HYPERGENES Discovery 
DNA was extracted from peripheral blood with standard procedures. 
In the discovery phase all samples were genotyped using the Illumina 1M-duo arrays 
(Illumina Inc, San Diego, CA, USA). The chip captures 1,199,187 SNPs. In addition to 
markers necessary for broad genome coverage the chip contains 21,877 non-synonymous 
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SNPs, 51,207 SNPs in sex chromosomes, 138 in mitochondrial DNA, 35,969 SNPs covering 
recently reported copy number variant regions, 30,908 SNPs in MHC and ADME regions. 
Genotyping was performed in two different genotyping centres: Milan University (UNIMI) 
and Lausanne University (UNIL). UNIMI genotyped 2,064 subjects (1,270 controls and 794 
cases) whereas UNIL performed the genotyping of 1,995 subjects (665 controls and 1,330 
cases). 
All raw intensity data were collected in UNIMI genotyping centre and analyzed with the 
Illumina Software Genome Studio for genotype calling, using the Illumina reference 
cluster file. A DNA call rate threshold was set at 0.95 and DNAs with call rate ≤ 0.95 were 
excluded from the final data set. For each DNA, data from X chromosome were used to 
check for discordance with ascertained sex. 
After association analysis, a final assessment of genotype quality was performed for the 
significantly associated SNPs (p-value<1·10
-4
) with visual inspection of cluster plots. As 
genotyping was performed in two Laboratories, replications were designed in order to 
estimate the genotyping error rate between the two Genotyping Centres. DNAs from 20 
individuals were genotyped with the 1M-duo Illumina's BeadChips. 
Within samples with Call Rates >0.95, 99.624% of the genotype calls were concordant and 
0.376% were discordant. A cross-check between the scan performances of the two 
Illumina iScan platforms was also performed. Ten chips (20 samples) were processed and 
scanned in UNIMI (average DNA call rate 0.994). The same chips were re-scanned in UNIL. 
We could demonstrate that 99.189% of the calls were concordant and 0.0053% was 
discordant between the two platforms. For 0.805% of the calls we could not do the 
comparison since this percentage accounts for calls available in the chip scanned in one 
Lab but not in the other and vice-versa. 
3.4.2. Genotyping and data filtering in HYPERGENES Validation 
Genotyping was performed on 2,869 samples by Milan University (UNIMI) and Lausanne 
University (UNIL), who genotyped 1,700 and 1,169 samples respectively, for 14,055 SNPs, 
using an Illumina custom chip (15K) built ad hoc on the basis of the Discovery results. All 
raw intensity data were collected in UNIMI genotyping centre and analyzed with the 
Illumina Software Genome Studio. For custom chips Illumina doesn’t supply the reference 
cluster file for genotype calling, we therefore ran training samples to generate a reference 
cluster file. To create this file all SNPs were visually inspected in order to check the 
accuracy of the cluster plots. Three hundred and forty ambiguous SNPs were excluded. 
Genotype calling for the whole sample was performed using the custom reference file. In 
the Validation phase the DNA call rate threshold was set at 0.98 and this led to the 
exclusion of 173 DNAs from the final data set that comprised of 2,696 DNAs. 
3.4.3. Genotyping and data filtering in Epogh Flemengho Population based study 
Genotyping was performed on 3,430 samples by Milan University (UNIMI) and Lausanne 
University (UNIL), who genotyped 192 and 3,238 samples respectively for 14,055 SNPs, 
using the 15K Illumina custom chip. All raw intensity data were collected in UNIMI 
genotyping centre and analyzed with the Illumina Software Genome Studio.  
Genotype calling for the whole sample was performed using the custom reference file 
previously generated. The DNA call rate threshold was set at 0.98 and this led to the 
exclusion of 533 DNAs from the final data set that comprised of 2,897 DNAs. 
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3.5. Statistical softwares 
3.5.1. PLINK 
PLINK [46]
 
is a free, open-source whole genome association analysis toolset, designed to 
perform a range of basic, large-scale analyses in a computationally efficient manner. The 
focus of PLINK is purely on analysis of genotype/phenotype data. PLINK is being 
developed by Shaun Purcell at the Center for Human Genetic Research (CHGR), 
Massachusetts General Hospital (MGH), and the Broad Institute of Harvard & MIT, with 
the support of others. 
3.5.2. Eigensoft 
The Eigensoft package (version 3.0 for Linux platform, Department of Genetics, Harvard 
Medical School, Boston, USA) combines functionality from population genetics methods 
and EIGENSTRAT stratification correction method [47, 48]. The EIGENSTRAT method uses 
principal components analysis to explicitly model ancestry differences between cases and 
controls along continuous axes of variation; the resulting correction is specific to a 
candidate marker’s variation in frequency across ancestral populations, minimizing 
spurious associations while maximizing power to detect true associations. The EIGENSOFT 
package has a built-in plotting script and supports multiple file formats and quantitative 
phenotypes. 
3.5.3. STATA SE 
STATA SE (Version 11) is a commercial data analysis and Statistical software. The software 
offers different tools to data analysis, management, graphics, matrix language, linear 
models, survey statistics, multivariate methods, multinomial etc. 
3.5.4. R 
R (version 2.14.1 Copyright 2011 The R Foundation for Statistical Computing) is a free 
language and environment for statistical computing and graphics. It is a GNU project 
similar to the S language and environment, which was developed at Bell Laboratories 
(formerly AT&T, now Lucent Technologies) by John Chambers and colleagues. R can be 
considered as a different implementation of S. R provides a wide variety of statistical 
(linear and nonlinear modeling, classical statistical tests, time-series analysis, 
classification, clustering) and graphical techniques, it is highly extensible and presents 
some packages implementing statistical methods and algorithms for the analysis of 
genetic data and for related population genetics studies. 
Particularly we used GenABEL package, a widely used GWAS R package aiming to facilitate 
statistical analyses of GWAS data using fast procedures for specific genetic tests such as 
data quality control, testing of association of single nucleotide polymorphisms with binary 
or quantitative traits, visualization of results and easy interfaces to standard statistical and 
graphical procedures [49].  
3.6. Quality Control 
3.6.1. Quality Control on the HYPERGENES Discovery sample 
All QC steps were performed in accordance with the protocol written by C.A Anderson et 
al [50]. The HYPERGENES Discovery sample included 4,059 individuals genotyped for 1M 
SNPs. 143 Samples having Call Rate <0.95 were excluded. 56 subjects with genotypic sex 
mismatch (difference between the gender reported in clinical data and the one estimated 
with sex SNPs genotyped) were identified and removed from the analysis. Using genome-
wide IBD estimation (PLINK version 1.7 [46]) we identified and removed from the analysis 
 21 
64 duplicated and 156 related subjects (44 family components, 63 siblings, 23 
parent/offspring, 26 second degree).  
In this study, we selected a sample composed by hypertensives with eGFR data available 
(1,634 individuals). We performed a heterozigosity rate test (PLINK version 1.7) and based 
on this results (threshold: ± 3 sd from average) 22 subjects were excluded. Principal 
Component Analysis (PCA) was therefore performed on this sample, using the EIGENSOFT 
package (version 2.0) [47, 48]: 8 outliers were removed as individuals that exceed a 
default number of standard deviations (6.0) from the whole sample. After this quality 
control the final hypertensive sample comprised 1,604 individuals (1,083 males and 521 
females).  
173,624 SNPs with a minor allele frequency (MAF) <1% and 74,501 with call rate <99% 
were removed leaving 881,299 SNPs for analysis.  
3.6.2. Quality Control on the HYPERGENES Validation sample 
The HYPERGENES Validation sample was composed by 2,696 individuals genotyped using 
the 15K custom chip. After data quality control for relatedness/duplicates (32 duplicated 
and 33 related subjects) the final case-control sample was composed by 2,631 subjects, 
1,385 hypertensives and 1,246 controls (1,417 males and 1,214 females).  
We selected a hypertensive sample of 1,198 individuals with eGFR data. A heterozigosity 
rate test (PLINK version 1.7) was performed and 12 individuals were excluded (threshold: 
± 3 sd from average). Principal Component Analysis (PCA) was then performed using the 
EIGENSOFT package (version 2.0). 3 outliers were removed as individuals that exceed a 
default number of standard deviations (6.0) from the whole sample. 
200 SNPs were filtered out on the basis of SNP genotype call rates (<99%) and 2,657 SNPs 
for MAF (MAF<0.01). After quality control the final hypertensive sample comprised 1,183 
individuals and 10,800 SNPs. 
3.6.3. Quality Control on the Epogh Flemengho Population based study 
The Epogh Flemengho Population based sample was composed by 2,897, genotyped using 
the 15K custom chip. After data quality control for duplicates (59 duplicated subjects) the 
final case-control sample was composed by 2,838 subjects.  
We analyzed 2,697 subjects in the Cross sectional analysis and 1,951 individuals for the 
Longitudinal study. In the Cross sectional analysis 462 SNPs were excluded for low call rate 
(< 99%) while 2,749 SNPs for Minor Allele Frequency (< 0.01): 10,527 SNPs were therefore 
available for the analysis. In the Longitudinal study 491 SNPs were excluded for low call 
rate (< 99%) and 2,764 SNPs for Minor Allele Frequency (< 0.01): 10,483 SNPs were finally 
available for the analysis. 
3.6.4. Quality control summary 
The following table (6) resumes the number of SNPs and subjects used in each analysis. 
 
Study Samples SNPs 
HYPERGENES Discovery analysis 1,604 881,299 
HYPERGENES Validation analysis 1,183 10,800 
Population based: Cross sectional analysis 2,697 10,527 
Population based: Longitudinal analysis 1,951 10,483 
Table 6: Summary of number of subjects and SNPs analyzed in each analysis. 
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3.7. Statistical Analysis 
3.7.1. HYPERGENES hypertensive sample  
The basic statistical analyses were performed in accordance with the protocol written by 
G.M. Clarke et al [51]. In the HYPERGENES Discovery sample, each SNP was tested for 
association with eGFR using a linear regression under an additive model with adjustment 
for sex, age, body mass index, systolic blood pressure, diastolic blood pressure, 
antihypertensive treatment (Y/N), ethnic group and for the first 10 PCs, as implemented in 
PLINK.  
In the Validation phase, linear regression analysis was carried out using an additive 
genetic model adjusted for sex, age, body mass index, systolic blood pressure, diastolic 
blood pressure, antihypertensive treatment, ethnic group and for the first 10 PCs. 
Combined analysis for HYPERGENES discovery and CKDGen Meta-analysis results was 
conducted using both Z-score and inverse variance weighting meta-analysis as 
implemented in METAL [52]. 
3.7.2. Population Based study  
In the Cross sectional study each SNP was tested for association with eGFR using a 
polygenic model with mmscore as implemented in R, GenABEL package [53, 54, 55, 56, 
49]. The model was adjusted for pedigree (random effect), sex, age, body mass index, 
systolic and diastolic blood pressure, antihypertensive treatment (Y/N) and recruitment 
centre (fixed effects).  
In the Longitudinal study each SNP was tested for association with delta eGFR using a 
polygenic model with mmscore as implemented in R, GenABEL package [53, 54, 55, 56, 
49]. Delta eGFR was calculated as the last available eGFR minus the baseline eGFR. The 
model was adjusted for pedigree (random effect), age at baseline, eGFR at baseline, 
gender, BMI at baseline, time to follow up, centre (fixed effects). 
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4. RESULTS 
4.1. Sample Characteristics  
4.1.1. HYPERGENES Discovery and Validation Sample 
We studied 1,634 hypertensive subjects from the HYPERGENES Discovery phase and 1,198 
hypertensives from the HYPERGENES Validation phase. Characteristics of the study 
samples, detailed by ethnic groups, are reported in table 7 and 8. The mean age of the 
Discovery participants varied from 45 years in south Europe subjects to 50 years in 
Sardinia subjects and from 42 to 50 years in the south Europe and Sardinia Validation 
groups respectively. The mean observed eGFR across the three ethnic groups ranged from 
80.78 ml/min/1.73m
2
 (north Europe) to 95.49 ml/min/1.73m
2
 (south Europe) in the 
Discovery sample and from 83.49 ml/min/1.73m
2
 (north Europe) to 97.33 ml/min/1.73m
2
 
(south Europe) in the Validation sample. eGFR distribution in the two study groups is 
presented in figure 3 and 4. The mean eGFR in males and females is significantly different 
in both groups, with a p-value ≤ 10
-5
: eGFR distribution according to sex for the 
HYPERGENES Discovery and Validation samples is shown in table 9 and 10.  Figure 5 and 6 
show the distribution of eGFR by decade in the two groups; as previously mentioned, GFR 
declines with normal ageing usually begin after 30–40 years of age and the rate of decline 
may accelerate after age of 50-60 years: in the Discovery sample it is possible to notice 
the expected eGFR plateau until 40 years old followed by a progressive decrease (figure 
5). 
 North Europe Sardinia South Europe 
Number of subjects (%) 410  684  510  
Number (%) with characteristic 
Women 45.61  32.46  21.96  
Treated for hypertension  56.83  0  1.18  
Mean (SD) characteristic       
SBP (mm Hg) 141.90 (20.26) 158.46 (14.47) 148.36 (9.04) 
DBP (mmHg) 89.43 (12.19) 102.44 (8.97) 96.35 (5.80) 
Age (yrs) 46.74 (9.29) 50.77 (10.60) 45.39 (8.05) 
Body mass index (kg/m
2
) 27.90 (5.23) 27.48 (3.86) 26.50 (3.11) 
eGFR 80.78 (16.46) 84.54 (18.20) 95.49 (18.90) 
Serum Creatinine 0.97 (0.19) 0.95 (0.19) 0.89 (0.15) 
 
 
 
Table 7: Discovery sample description by ethnic group. 
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 North Europe Sardinia South Europe 
Number of subjects (%) 588  372  238  
Number (%) with 
characteristic 
      
Percent women (%) 47.45  48.66  18.91  
SBP (mm Hg) 152.43 (20.62) 158.96 (13.83) 150.22 (14.47) 
DBP (mmHg) 95.76 (12.76) 101.83 (7.96) 97.01 (9.75) 
age (yrs) 46.9 (8.2) 50.18 (10.14) 42.9 (8.25) 
body mass index (kg/m
2
) 26.2 (4.29) 27.41 (4.29) 26.36 (3.10) 
Treated for hypertension (%) 72.45  0  13.87  
eGFR 83.49 (18.71) 90.83 (20.70) 97.33 (19.29) 
Serum Creatinine 0.95 (0.25) 0.86 (0.15) 0.8925 (0.16) 
 
 
 
 
 
 
 
 
 
 
 
Table 8: Validation sample description by ethnic group. 
 
Figure 3: Histogram of eGFR distribution in the Discovery sample. 
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Variable Sample N Mean Std. Dev. Min Max 
eGFR 
All 1,604 87.06 18.95 28.18 174.81 
Males 1,083 90.71 18.27 35.24 165.18 
Females 521 79.48 18.08 28.18 174.81 
 
 
Variable Sample Obs Mean Std. Dev. Min Max 
eGFR 
All 1,183 88.63 20.12 19.08 203.48 
Males 686 91.82 18.71 27.54 167.22 
Females 497 84.22 21.16 19.08 203.48 
 
 
 
Figure 4: Histogram of eGFR distribution in the Validation sample. 
 
Table 9: eGFR distribution according to gender in the Discovery sample. 
 
Table 10: eGFR distribution according to sex in the Validation sample. 
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Figure 6: Distribution of eGFR by decade in the Validation sample. 
 
Figure 5: Distribution of eGFR by decade in the Discovery sample. 
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4.1.2. Population Based Sample 
For the Cross sectional study we analyzed 2,697 subjects from the EPOGH-FLEMENGHO 
cohort used in the Cross sectional study. A subset of 1,952 subjects from the same cohort 
was used in the Longitudinal study. Characteristics of the study samples are reported in 
table 11. The mean age of the Cross sectional sample was 39 years while it ranged from 40 
years at the baseline measurement to 48 years at the follow-up measurement in the 
Longitudinal study. The mean observed eGFR was 83.49 ml/min/1.73m
2
 in the Cross 
sectional sample and ranged from 84.86 at baseline to 84.26 at follow-up in the 
Longitudinal group. The mean eGFR value is significantly different between baseline and 
follow-up measurement (p-value=0.03). The distribution of eGFR in the Cross sectional 
sample and the distribution of delta eGFR in the Longitudinal sample are presented in 
figures 7 and 8. Finally, figure 9 reports the distribution of eGFR by decade in the Cross 
sectional sample. 
 Cross Sectional Longitudinal 
Percent women (%) 51.28  52.49  
SBP (mm Hg) baseline 124.31 (17.04)   
DBP (mmHg) baseline 76.39 (11.26)   
Age (yrs) baseline 39.31 (15.99) 39.96 (15.16) 
Age (yrs) follow up   47.83 (16.14) 
Body Mass Index (kg/m
2
) 
baseline 
25.1 (4.7) 25.28 (4.64) 
Treated for hypertension (%) 11.38    
eGFR baseline 83.49 (20.31) 84.86 (19.9) 
eGFR follow up   84.26 (20.18) 
Serum Creatinine baseline 0.98 (0.18) 0.97 (0.19) 
Serum Creatinine follow up   0.93 (0.26) 
 
 
 
 
 
Table 11: Population based sample description. 
 
 28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Delta eGFR distribution in the Longitudinal sample. 
 
Figure 7: eGFR distribution in the Cross sectional sample. 
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4.2. Results of the Genome-wide study 
4.2.1. HYPERGENES Discovery and Validation Analysis 
Best results of the single SNP analysis are reported in table 12 for the Discovery sample 
and table 13 for the Validation sample. Rs4678878 reaches, in the Discover sample, the 
genome-wide significance (3.83x10
-8
). The first two findings of the Discovery sample, 
rs4678878 and rs11129714, map in STAC gene, which encodes for a SH3 and cysteine rich 
domain protein involved in a neuron-specific signal transduction pathway. In the 
Validation analysis none of the SNPs reach the Bonferroni significance threshold at 10
-6
 
(calculated on the basis of the SNPs present on 15K custom chip).  In this study, five 
markers (rs7666226, rs7666425, rs13150531, rs13114026, rs10014602), having a p-value 
10
-4
, lie in PIGG gene, coding for an ethanolamine phosphate transferase involved in 
glycosyl phosphatidyl inositol anchor biosynthesis. Rs802374, rs17142666, rs17142724 
and rs17142737 (p-value =10 
-4
) are localized in KCND2 gene coding for a potassium 
voltage-gated channel; mutations in this gene are implicated in cardiac conduction 
disorders.
Figure 9: Distribution of eGFR by decade in the Cross sectional sample. 
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CHR SNP BP 
EFFECT  
ALLELE 
BETA SE P GENE POSITION 
DISTANCE 
TO GENE 
3 rs4678878 36445311 G -3.421 0.6191 3.83x10
-8
 STAC intron -14549 
3 rs11129714 36448844 G -3.257 0.6381 3.74x10
-7
 STAC intron -11016 
9 rs10809319 11054428 A -3.006 0.6343 2.34x10
-6
 LOC646087 flanking_5UTR -234120 
3 rs9311801 6149815 A 3.913 0.8469 4.14x10
-6
 GRM7 flanking_5UTR -728112 
13 rs9557072 98238372 G -2.696 0.6057 9.14x10
-6
 DOCK9 flanking_3UTR -5373 
12 rs4765044 124547089 A 2.825 0.6375 1.00x10
-5
 TMEM132B intron -22849 
22 rs16989636 30638680 G -12.57 2.846 1.08x10
-5
 DEPDC5 flanking_3UTR -5679 
4 rs2046770 169534575 G 2.856 0.6484 1.13x10
-5
 DDX60L intron -1325 
17 rs2659030 76792569 A -2.645 0.602 1.19x10
-5
 AZI1 intron -567 
8 rs11784679 22887095 C 2.98 0.6816 1.31x10
-5
 RHOBTB2 flanking_5UTR -26312 
5 rs216124 149442202 A 3.263 0.7494 1.42x10
-5
 CSF1R intron -1422 
13 rs6490699 21614323 A 3.413 0.7848 1.45x10
-5
 FGF9 flanking_3UTR -440136 
16 rs9930152 48389067 A -2.694 0.6228 1.61x10
-5
 ZNF423 intron -8109 
9 rs10733219 11068006 G -2.656 0.6197 1.92x10
-5
 LOC646087 flanking_5UTR -247698 
13 rs772311 98266480 C 2.652 0.6197 1.99x10
-5
 DOCK9 intron -5934 
7 rs889870 137302692 A 4.524 1.059 2.06x10
-5
 CREB3L2 intron -34198 
4 rs12499919 115391056 A 3.197 0.7506 2.17x10
-5
 ARSJ flanking_5UTR -270530 
21 rs6517073 32351155 G 2.773 0.6519 2.23x10
-5
 HUNK flanking_3UTR -52907 
19 rs467439 6867493 G 2.579 0.607 2.28x10
-5
 EMR1 intron -114 
3 rs728082 36425383 A -2.741 0.6469 2.40x10
-5
 STAC intron -28133 
1 rs570762 176156776 A 2.636 0.6242 2.56x10
-5
 SEC16B flanking_3UTR -8128 
7 rs6973843 105773180 A -4.213 1.003 2.82x10
-5
 PBEF1 flanking_5UTR -60587 
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CHR SNP BP 
EFFECT  
ALLELE 
BETA SE P GENE POSITION 
DISTANCE 
TO GENE 
5 rs1215655 3223620 A 2.522 0.6014 2.89x10
-5
 LOC729099 flanking_5UTR -275739 
9 rs6474626 11069752 A -2.598 0.6205 2.98x10
-5
 LOC646087 flanking_5UTR -249444 
1 rs11210537 42118310 A -2.682 0.6434 3.23x10
-5
 HIVEP3 intron -38361 
9 rs10809326 11065596 A -2.665 0.6423 3.52x10
-5
 LOC646087 flanking_5UTR -245288 
5 rs778447 66314470 A 3.929 0.9471 3.53x10
-5
 MAST4 intron -3558 
6 rs9295289 158387494 G -5.527 1.335 3.63x10
-5
 SYNJ2 intron -3075 
3 rs4505641 36407085 G 2.531 0.6129 3.82x10
-5
 STAC intron -9835 
1 rs12024772 42125931 G -2.639 0.6402 3.95x10
-5
 HIVEP3 intron -30740 
15 rs2387110 89672208 G 2.624 0.6369 3.99x10
-5
 SV2B flanking_3UTR -32554 
2 rs6546443 68952977 A -2.601 0.6334 4.23x10
-5
 BMP10 flanking_5UTR -824 
16 rs17752673 47034594 A 3.189 0.7798 4.53x10
-5
 LOC643114 flanking_5UTR -12362 
15 rs8024792 47881243 G -2.832 0.6928 4.58x10
-5
 LOC645453 flanking_3UTR -5081 
2 rs11676320 232890310 G 4.697 1.149 4.60x10
-5
 DIS3L2 intron -12530 
1 rs12030998 57957630 A 3.911 0.9588 4.76x10
-5
 DAB1 intron -69705 
2 rs3817368 68951366 C -2.573 0.632 4.90x10
-5
 BMP10 intron -295 
11 rs12363667 43657386 A 5.015 1.234 5.10x10
-5
 HSD17B12 flanking_5UTR -1495 
21 rs2835144 36121367 G -2.458 0.6052 5.13x10
-5
 SETD4 flanking_3UTR -207342 
11 rs487518 131283728 A -2.396 0.5926 5.54x10
-5
 HNT flanking_5UTR -2194 
18 rs275875 20105278 G -2.435 0.603 5.64x10
-5
 OSBPL1A intron -306 
2 rs1370650 140113214 A 2.697 0.6679 5.66x10
-5
 LRP1B flanking_3UTR -592252 
16 rs7197521 47031763 G 3.408 0.8453 5.79x10
-5
 LOC643114 flanking_5UTR -15193 
2 rs2312078 68948656 G -2.537 0.631 6.07x10
-5
 BMP10 intron -1449 
 32 
CHR SNP BP 
EFFECT  
ALLELE 
BETA SE P GENE POSITION 
DISTANCE 
TO GENE 
11 rs11037553 43653467 A 4.948 1.231 6.08x10
-5
 HSD17B12 flanking_5UTR -5414 
9 rs10738194 10921959 A -2.385 0.5933 6.10x10
-5
 LOC646087 flanking_5UTR -101651 
6 rs1075379 33845778 G 2.916 0.7254 6.10x10
-5
 LEMD2 flanking_3UTR -1190 
11 rs522856 131283569 C -2.387 0.5939 6.12x10
-5
 HNT flanking_5UTR -2353 
15 rs4551980 47910160 A -2.749 0.684 6.13x10
-5
 ATP8B4 flanking_3UTR -27567 
19 rs2276470 50666508 A 2.458 0.6129 6.37x10
-5
 FOSB intron -109 
15 rs7182178 47911691 A -2.743 0.684 6.37x10
-5
 ATP8B4 flanking_3UTR -26036 
9 rs10815718 7925389 G -3.2 0.7982 6.37x10
-5
 C9orf123 flanking_5UTR -135590 
2 rs1438026 140057490 G 2.641 0.66 6.56x10
-5
 LRP1B flanking_3UTR -647976 
10 rs2758965 77749539 A 6.183 1.545 6.57x10
-5
 C10orf11 intron -4626 
3 rs6798664 6184095 G 2.637 0.6596 6.67x10
-5
 GRM7 flanking_5UTR -693832 
19 rs2276469 50666433 G 2.449 0.6133 6.83x10
-5
 FOSB intron -34 
3 rs9811274 144830174 A -2.469 0.6185 6.86x10
-5
 SLC9A9 intron -23613 
10 rs967948 77748165 A 6.135 1.54 7.06x10
-5
 C10orf11 intron -6000 
18 rs1893468 53769609 A 3.451 0.8667 7.16x10
-5
 NEDD4L flanking_5UTR -93169 
2 rs3762613 68952476 G -2.515 0.6328 7.35x10
-5
 BMP10 flanking_5UTR -323 
2 rs12994269 115566962 A 4.208 1.059 7.44x10
-5
 DPP10 flanking_5UTR -69240 
18 rs4245295 53741452 A 2.847 0.7168 7.44x10
-5
 LOC284288 flanking_3UTR -84183 
3 rs7617700 36392255 G -2.66 0.6708 7.67x10
-5
 STAC flanking_5UTR -4846 
4 rs1946860 178404692 C -6.16 1.556 7.83x10
-5
 NEIL3 flanking_5UTR -63330 
6 rs7755323 33869137 G 2.892 0.7322 8.15x10
-5
 MLN flanking_3UTR -1290 
5 rs7702151 141096026 G -2.415 0.6115 8.21x10
-5
 CENTD3 flanking_5UTR -54042 
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CHR SNP BP 
EFFECT  
ALLELE 
BETA SE P GENE POSITION 
DISTANCE 
TO GENE 
5 rs2359425 76193792 A 5.172 1.311 8.29x10
-5
 S100Z intron -7955 
9 rs4421446 11083422 A -2.526 0.6406 8.42x10
-5
 LOC646087 flanking_5UTR -263114 
6 rs9346649 168233081 A 2.418 0.6152 8.86x10
-5
 FRMD1 flanking_5UTR -10393 
1 rs10797912 182051797 G -5.454 1.388 8.92x10
-5
 RGL1 intron -9555 
5 rs4380707 41441161 A 3.763 0.9579 8.92x10
-5
 PLCXD3 intron -22768 
13 rs7997540 20548501 C 3.11 0.7921 8.98x10
-5
 LATS2 flanking_5UTR -14847 
5 rs11956840 76191426 A 5.251 1.338 9.03x10
-5
 S100Z intron -9690 
13 rs9571607 66102132 A 2.521 0.6424 9.09x10
-5
 PCDH9 intron -1211 
10 rs1408405 9398374 A -5.603 1.429 9.17x10
-5
 LOC389936 flanking_5UTR -90656 
2 rs4954786 140077226 G 2.611 0.6667 9.38x10
-5
 LRP1B flanking_3UTR -628240 
16 rs6498964 63502473 G 7.564 1.933 9.48x10
-5
 CDH11 flanking_3UTR -35711 
18 rs1539932 53761811 G 2.799 0.7153 9.52x10
-5
 NEDD4L flanking_5UTR -100967 
7 rs454066 51998407 A -2.548 0.6514 9.54x10
-5
 LOC642663 flanking_3UTR -580450 
4 rs13137544 190229767 A -2.453 0.6271 9.57x10
-5
 LOC728856 flanking_3UTR -130677 
3 rs4678874 36432376 G -2.688 0.6881 9.74x10
-5
 STAC intron -27484 
1 rs10493043 30418573 G -3.117 0.7984 9.85x10
-5
 MATN1 flanking_3UTR -540010 
4 rs10520439 181002632 A -2.621 0.6717 9.93x10
-5
 LOC643179 flanking_3UTR -729074 
2 rs1347729 140039735 A 2.601 0.6669 9.98x10
-5
 LOC129560 flanking_5UTR -662948 
 
 
Table 12: Best Discovery Analysis Results (p-value ≤ 10
-5
). The results are ranked in a descending order of p-value. For each SNP, 
chromosome, position, effect allele, beta and related standard error, p-value, gene, position relative to gene and distance to gene are 
reported.  
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CHR SNP BP 
EFFECT 
ALLELE 
BETA SE P GENE POSITION 
DISTANCE TO 
GENE 
18 rs1905641 61714830 A 6.569 1.716 1.36x10
-4
 CDH7 flanking_3UTR -15676 
4 rs7666226 507376 G 4.039 1.084 2.04x10
-4
 PIGG coding [128/326] 
4 rs7666425 507461 G 4.039 1.084 2.04x10
-4
 PIGG coding [213/241] 
6 rs9462639 40727471 A 11.24 3.053 2.42x10
-4
 LRFN2 flanking_5UTR -64367 
4 rs13150531 507622 A 3.905 1.086 3.36x10
-4
 PIGG coding [374/80] 
4 rs13114026 510853 A 3.883 1.088 3.75x10
-4
 PIGG coding [25/166] 
7 rs802374 119960866 A -9.812 2.787 4.47x10
-4
 KCND2 intron -199327 
7 rs17142666 119777393 G -9.695 2.869 7.51x10
-4
 KCND2 intron -74356 
9 rs7034422 118667250 A -4.22 1.251 7.69x10
-4
 ASTN2 intron -1417 
5 rs891921 168145529 A 4.424 1.316 8.00x10
-4
 SLIT3 coding [39/32] 
19 rs8104211 11591545 A -2.75 0.8242 8.74x10
-4
 ZNF627 flanking_3UTR -571 
4 rs10014602 524965 G 3.666 1.102 9.11x10
-4
 PIGG flanking_3UTR -1653 
7 rs17142724 119853752 A -8.951 2.704 9.60x10
-4
 KCND2 intron -150715 
7 rs17142737 119861886 A -8.951 2.704 9.60x10
-4
 KCND2 intron -158849 
6 rs9475417 55796320 G 3.254 0.9851 9.83x10
-4
 BMP5 intron -3716 
 
 
 
 
Table 13: Best Validation Analysis Results (p-value ≤ 10
-4
). For each SNP chromosome, position, effect allele, beta and related standard 
error, p-value, gene, position relative to gene and distance to gene are reported. 
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4.2.2. Population-based study Analysis 
Best hits from the Cross sectional and Longitudinal analyses are reported in table 14 and 
15 respectively. In these analyses no SNPs reach the Bonferroni significance threshold of 
10
-6
 (based on the number of SNPs present in the custom chip). In the Cross sectional 
study, rs5767743 and rs5766743 map in PPARA gene, that encodes for a peroxisome 
proliferator-activated receptor alpha; this protein has two functions: 1) it is a transcription 
factor activated by oleoylethanolamide, a naturally occurring lipid that regulates satiety, 
2) it is a receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids 
involved in cardiovascular and metabolic pathways. The 3 best findings of the Longitudinal 
study (rs7730041, rs10067052, rs4867490), having p-value 10
-5
, are located in LOC340113 
which function is unknown. Rs3890733, p-value = 5.94X10
-4
 maps in VDR gene, the vitamin 
D receptor. Vitamin D deficiency has been reported as an underestimated risk factor for 
cardiovascular disease in patients with chronic kidney disease [57].  
 
4.2.3. Comparative Results 
Table 16 shows the cross-check analysis between the different studies (Discovery, 
Validation, Cross-sectional and Longitudinal study). In particular, the table reports the 
results in the different studies for markers having a significance p-value less or equal to 
10
-4
 in the Discovery sample. No SNP has been validated with significant p-values.  
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CHR SNP BP 
EFFECT  
ALLELE 
BETA SE P GENE POSITION 
DISTANCE TO 
GENE 
22 rs5767743 45000657 G 2.26312 0.573589 7.96x10
-5
 PPARA intron -3634 
16 rs4781967 17529520 A -1.9564 0.548865 3.65x10
-4
 XYLT1 flanking_5UTR -57282 
13 rs17056501 37192478 A 2.811752 0.790778 3.77x10
-4
 TRPC4 intron -25595 
22 rs5766743 44986041 G 1.777124 0.533238 8.60x10
-4
 PPARA intron -3692 
 
 
 
 
 
 
 
 
 
 
 
 
Table 14: Best Cross sectional analysis results (p-value ≤ 10
-4
). For each SNP, chromosome, position, effect allele, beta and related 
standard error, p-value, gene, position relative to gene and distance to gene are reported. 
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CHR SNP BP 
EFFECT  
ALLELE 
BETA SE P GENE POSITION 
DISTANCE 
TO GENE 
5 rs7730041 32986121 G 2.35109 0.535683 1.25x10
-5
 LOC340113 coding [143/24] 
5 rs10067052 32976917 A 2.274925 0.537495 2.52x10
-5
 LOC340113 flanking_5UTR -6388 
5 rs4867490 32955758 A 2.174796 0.537612 5.66x10
-5
 LOC340113 flanking_5UTR -27547 
8 rs2059652 18901785 A 2.146122 0.552253 1.10x10
-4
 PSD3 intron -13567 
18 rs16960057 32120092 A -4.74426 1.222113 1.12x10
-4
 FHOD3 flanking_5UTR -11607 
10 rs9732211 128666930 G -1.88228 0.503303 1.97x10
-4
 DOCK1 intron -689 
3 rs925819 2847153 G 3.527368 0.951663 2.25x10
-4
 CNTN4 intron -10889 
16 rs2897205 57038642 A -4.42194 1.196842 2.35x10
-4
 NDRG4 flanking_5UTR -16475 
11 rs11020063 92182121 A -1.94493 0.559552 5.41x10
-4
 FAT3 intron -535 
12 rs3890733 46575639 A -1.84173 0.533771 5.94x10
-4
 VDR intron -4247 
4 rs7661978 100503221 A -2.05162 0.598138 6.40x10
-4
 ADH1C flanking_5UTR -10282 
3 rs2616570 2602816 A 1.698215 0.501791 7.55x10
-4
 CNTN4 intron -14575 
 
 
 
 
 
 
Table 15: Best Longitudinal analysis results (p-value ≤ 10
-4
). For each SNP, chromosome, position, effect allele, beta and related 
standard error, p-value, gene, position relative to gene and distance to gene are reported. 
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Chr SNP BP 
Effect 
Allele 
BETA 
 Disc  
SE  
Disc  P Disc  
BETA 
 Val  
SE  
Val  P Val  
BETA 
Cross 
SE  
Cross P Cross 
BETA  
Long 
SE  
Long P Long 
3 rs4678878 36445311 G -3.421 0.619 3.83x10-8 0.259 0.755 7.32x10-1 -0.319 0.466 4.94x10-1 -0.333 0.519 5.24x10-1 
22 rs16989636 30638680 G -12.570 2.846 1.08x10-5 6.111 3.552 8.56x10-2        
15 rs2387110 89672208 G 2.624 0.637 3.99x10-5 0.387 0.809 6.32x10-1 0.258 0.485 5.95x10-1 -0.200 0.539 7.12x10-1 
2 rs334162 127980901 A -4.943 1.292 1.36x10-4 -0.320 1.718 8.52x10-1 -0.449 1.094 6.81x10-1 -1.255 1.164 2.83x10-1 
2 rs334142 127953892 G -4.956 1.298 1.39x10-4 -1.331 1.753 4.48x10-1 -0.305 1.103 7.82x10-1 -1.108 1.177 3.49x10-1 
2 rs777559 127955490 A -4.954 1.298 1.41x10-4 -1.331 1.753 4.48x10-1 -0.305 1.103 7.82x10-1 -1.108 1.177 3.49x10-1 
2 rs2078028 127980716 G -4.943 1.298 1.45x10-4 -1.331 1.753 4.48x10-1 -0.298 1.103 7.87x10-1 -1.112 1.177 3.47x10-1 
1 rs3813649 176169348 A -2.592 0.687 1.67x10-4 -0.489 0.889 5.82x10-1 -0.083 0.543 8.79x10-1 0.186 0.602 7.58x10-1 
2 rs334149 127971354 G -4.845 1.289 1.78x10-4 -1.333 1.734 4.42x10-1 -0.305 1.103 7.82x10-1 -1.108 1.177 3.49x10-1 
2 rs6731270 127978345 G -4.845 1.289 1.78x10-4 -1.333 1.734 4.42x10-1 -0.305 1.103 7.82x10-1 -1.108 1.177 3.49x10-1 
15 rs17364665 46672121 C -4.560 1.274 3.54x10-4 -0.523 1.493 7.26x10-1 0.779 0.864 3.67x10-1 -0.448 0.978 6.49x10-1 
14 rs7153295 98836375 A -2.346 0.663 4.17x10-4 1.256 0.839 1.34x10-1 0.415 0.509 4.14x10-1 -0.104 0.563 8.55x10-1 
1 rs7522194 176172092 A -2.415 0.697 5.47x10-4 -0.404 0.894 6.51x10-1 0.026 0.549 9.62x10-1 0.030 0.606 9.61x10-1 
1 rs11119014 206457721 G -4.812 1.393 5.66x10-4 -0.681 1.797 7.05x10-1 0.281 0.867 7.46x10-1 -0.983 0.978 3.17x10-1 
16 rs3803667 48227891 G 2.633 0.765 5.91x10-4 -0.900 0.999 3.68x10-1 0.145 0.558 7.94x10-1 -0.892 0.629 1.58x10-1 
8 rs10105026 85313533 A -2.111 0.614 6.03x10-4 -0.858 0.759 2.59x10-1 0.037 0.456 9.35x10-1 -0.137 0.500 7.85x10-1 
6 rs1043784 7826930 G 3.061 0.901 6.94x10-4 -0.053 1.151 9.63x10-1 -0.470 0.753 5.32x10-1 -0.421 0.828 6.13x10-1 
1 rs3738081 37097270 C -2.264 0.679 8.80x10-4 -0.196 0.835 8.15x10-1 -0.028 0.535 9.58x10-1    
1 rs12067006 37097522 G -2.240 0.674 9.15x10-4 -0.296 0.840 7.25x10-1 -0.017 0.534 9.74x10-1 -0.394 0.569 4.90x10-1 
1 rs2334915 115802203 A -2.088 0.632 9.76x10-4 -0.565 0.775 4.66x10-1 0.026 0.464 9.56x10-1 0.299 0.513 5.62x10-1 
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Chr SNP BP 
Effect 
Allele 
BETA 
 Disc  
SE  
Disc  P Disc  
BETA 
 Val  
SE  
Val  P Val  
BETA 
Cross 
SE  
Cross P Cross 
BETA  
Long 
SE  
Long P Long 
8 rs13263453 18773776 A 3.113 0.943 9.85x10-4 1.517 1.147 1.86x10-1 1.231 0.733 9.33x10-2 -1.344 0.813 1.00x10-1 
19 rs8105305 43094939 A -1.979 0.600 9.93x10-4 -0.535 0.775 4.90x10-1 0.743 0.483 1.24x10-1 -0.434 0.533 4.18x10-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 16: Discovery SNPs with a p-value ≤ 10
-4
, that were on the 15K chip.  
Association results for the Discovery, Validation, Cross-sectional and Longitudinal studies are reported. 
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4.2.4. Principal Findings: STAC Gene 
The STAC gene was covered by 159 SNPs in the 1M chip used for the Discovery phase and 
just one SNP, rs4678878 (Pdisc=3.83x10
-8
), was present on the custom chip used for the 
Validation and Population based study. In the Discovery phase 15 SNPs in this gene reach 
a significance ranging from 3.83x10
-8
 (rs4678878) to 8.14x10
-3
 (rs11921700). They are 
presented in table 17. These markers are all located just before a hot-spot of 
recombination and map in the same linkage disequilibrium block; in fact the D’ between 
rs4678878, our best SNP, and each of the other 14 SNPs ranged from 1 to 0.638. 
Nevertheless, r
2
 ranged from 0.783 to 0.041 (figure 10 and table 18).  
In Validation and Population based study we do not replicate our best Discovery’s finding 
rs4678878: betaval=-3.421 and pval=7.32x10
-1
 in validation, betaCross=0.259 and 
pCross=4.94x10
-1
 in Cross-sectional and a betalong=-0.319 and plong=5.24x10
-1
 in Longitudinal 
study, respectively (Table 16).  
 
SNP BP 
Minor 
Allele 
BETA SE P 
rs4678878 36445311 G -3.421 0.6191 3.83x10
-8
 
rs11129714 36448844 G -3.257 0.6381 3.74x10
-7
 
rs728082 36425383 A -2.741 0.6469 2.40x10
-5
 
rs4505641 36407085 G 2.531 0.6129 3.82x10
-5
 
rs7617700 36392255 G -2.66 0.6708 7.67x10
-5
 
rs4678874 36432376 G -2.688 0.6881 9.74x10
-5
 
rs2361037 36404488 G -2.684 0.7028 1.39x10
-4
 
rs2885140 36429011 A -2.631 0.6893 1.40x10
-4
 
rs1531134 36400540 G -2.428 0.7257 8.39x10
-4
 
rs10514698 36439279 G -2.286 0.7102 1.32x10
-3
 
rs6550422 36395632 G -2.814 0.8865 1.53x10
-3
 
rs1598529 36452120 G -1.641 0.6093 7.17x10
-3
 
rs2127232 36380078 C -3.42 1.284 7.80x10
-3
 
rs11921700 36450546 A -3.277 1.237 8.14x10
-3
 
 
 
 
 
 
 
Table 17: Best SNPs localized in gene STAC analyzed in the Discovery 
sample. 
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A) 
B) 
Figure 10: Genetic association and LD distribution of the STAC gene:  
A) Regional association plot in the Hypergenes Discovery sample. Degree of 
association is expressed on the left. Recombination rate is expressed on the 
right.  
B) LD structure. The figure was made with Haploview software. 
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Best SNP other SNPs D' r
2
 
rs4678878 rs11129714 0.975 0.733 
rs4678878 rs11921700 1 0.107 
rs4678878 rs1598529 0.646 0.276 
rs4678878 rs10514698 0.965 0.475 
rs4678878 rs1531134 0.995 0.469 
rs4678878 rs2127232 0.638 0.041 
rs4678878 rs2361037 0.995 0.521 
rs4678878 rs2885140 0.968 0.525 
rs4678878 rs4505641 0.966 0.492 
rs4678878 rs4678874 0.968 0.525 
rs4678878 rs6550422 0.99 0.245 
rs4678878 rs728082 0.997 0.783 
rs4678878 rs7617700 0.908 0.531 
 
 
4.2.5. Meta-analysis with CKDGen consortium data 
In order to validate our Discovery results, we performed a meta-analysis between these 
findings and the CKDGen Consortium meta-analysis results [13, 32]. The meta-analysis 
was performed only for the SNPs that in both dataset presented a p-value lower than 10
-3
.  
The CKDGen Consortium analyzes renal function using three different phenotypes: 1) 
eGFR evaluated from serum creatinine; 2) eGFR evaluated from serum cystatin c and 3) 
CKD, defined as eGFRcrea < 60 ml/min/1.73m
2
.  We compared our best results with each 
of the three different phenotypes analyzed by the CKDGen consortium. Results are 
reported in table 19. Due to the different sample sizes, the meta-analysis results are 
strongly steered by CKDGen meta-analysis. 
Our best meta-analysis results map in the CST3_CST9 region (rs17751897, rs12625716, 
rs1158167), and in gene PRKAG2 (rs2536067). CST3_CST9 is a region that has been 
repeatedly associated with eGFR estimated from cystatin c [31, 32, 34] and PRKGA2 
encodes for the enzyme 5'-AMP-activated protein kinase subunit gamma-2. Mutations in 
PRKAG2 gene have been associated with ventricular pre-excitation (Wolff-Parkinson-
White syndrome), progressive conduction system disease and cardiac hypertrophy [13, 
32, 58].  
Table 18: D’ and r
2
 between our best SNP 
and the other best findings in STAC gene. 
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Marker 
Name 
Chr Position Gene 
BETA_disc  
(SE) 
P_disc 
BETA_CKDGen 
(SE) 
P_CKDGen 
BETA 
combined 
SE  
combined 
Inverse 
variance 
weighted P 
combined 
Z-score P 
combined 
eGFR Creatinine 
rs2536067 7 151056382 PRKAG2 2.121 (0.595) 3.75x10
-4
 -0.0063 (0.0013) 5.90x10
-7
 -0.0063 0.0013 1.21x10
-6
 4.81x10
-8
 
rs1444039 1 107750779 NTNG1 -2.576 (0.725) 3.94x10
-4
 -0.0039 (0.0013) 2.98x10
-3
 -0.0039 0.0013 2.64x10
-3
 5.56x10
-4
 
rs17115661 12 74454267 LOC390345 -2.218 (0.627) 4.18x10
-4
 -0.0038 (0.0013) 3.68x10
-3
 -0.0038 0.0013 3.55x10
-3
 1.82x10
-2
 
rs7815850 8 18782841 PSD3 2.922 (0.827) 4.22x10
-4
 -0.0044 (0.0016) 6.82x10
-3
 -0.0044 0.0016 6.09x10
-3
 3.04x10
-2
 
rs1041434 21 36561559 DOPEY2 -2.852 (0.809) 4.34x10
-4
 -0.0046 (0.0016) 3.84x10
-3
 -0.0046 0.0016 4.13x10
-3
 1.88x10
-2
 
rs11614414 12 74452811 LOC390345 -2.205 (0.628) 4.53x10
-4
 0.0038 (0.0013) 3.69x10
-3
 0.0038 0.0013 3.55x10
-3
 1.81x10
-2
 
rs17809619 3 20715647 LOC728976 -3.449 (0.989) 4.99x10
-4
 0.0079 (0.0021) 1.92x10
-4
 0.0079 0.0021 1.74x10
-4
 1.45x10
-3
 
rs4529500 8 18784118 PSD3 2.821 (0.812) 5.22x10
-4
 -0.0043 (0.0016) 9.08x10
-3
 -0.0043 0.0016 7.35x10
-3
 3.77x10
-2
 
rs7312284 12 74403903 LOC390345 -2.274 (0.655) 5.33x10
-4
 -0.0054 (0.0014) 1.07x10
-4
 -0.0054 0.0014 1.18x10
-4
 8.68x10
-4
 
rs920835 1 107748325 NTNG1 -2.498 (0.726) 5.98x10
-4
 -0.0039 (0.0013) 3.10x10
-3
 -0.0039 0.0013 2.65x10
-3
 6.17x10
-4
 
rs4256249 4 77677603 SHROOM3 -1.935 (0.617) 1.74x10
-3
 0.0047 (0.0013) 1.60x10
-4
 0.0047 0.0013 3.08x10
-4
 1.04x10
-3
 
eGFR Cystatin 
rs686053 1 46987372 KIAA0494 3.342 (0.9337) 3.55x10
-4
 -0.0094 (0.0032) 3.36x10
-3
 -0.0094 0.0032 3.18x10
-3
 6.26x10
-4
 
rs1566538 15 68142926 TLE3 2.617 (0.7576) 5.66x10
-4
 -0.0084 (0.0027) 1.88x10
-3
 -0.0084 0.0027 1.79x10
-3
 3.49x10
-4
 
rs6475827 9 2489345 VLDLR -2.261 (0.6544) 5.66x10
-4
 0.0088 (0.0025) 3.58x10
-4
 0.0088 0.0025 4.11x10
-4
 5.53x10
-5
 
rs17068808 3 63450334 SYNPR -2.115 (0.616) 6.10x10
-4
 0.0063 (0.0022) 4.32x10
-3
 0.0063 0.0022 4.03x10
-3
 8.96x10
-4
 
rs17751897 20 23540714 CST9 -2.455 (0.7162) 6.24x10
-4
 -0.0701 (0.0027)  1.69x10
-152
 -0.0701 0.0027   1.83x10
-148
 9.37x10
-144
 
rs10510168 3 1290929 CNTN6 3.481 (1.033) 7.73x10
-4
 -0.0097 (0.0036) 6.34x10
-3
 -0.0097 0.0036 7.30x10
-3
 2.69x10
-2
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Marker 
Name 
Chr Position Gene 
BETA_disc  
(SE) 
P_disc 
BETA_CKDGen 
(SE) 
P_CKDGen 
BETA 
combined 
SE  
combined 
Inverse 
variance 
weighted P 
combined 
Z-score P 
combined 
rs12625716 20 23554845 CST3 -2.399 (0.7168) 8.36x10
-4
 0.0702 (0.0027)   1.88x10
-152
 0.0702 0.0027 6.91x10
-149
 7.70x10
-144
 
rs10966539 9 2488434 VLDLR -2.31 (0.6925) 8.71x10
-4
 0.0082 (0.0026) 1.98x10
-3
 0.0082 0.0026 1.54x10
-3
 3.95x10
-4
 
rs7692604 4 163462185 FSTL5 -2.07 (0.6257) 9.59x10
-4
 -0.0071 (0.0024) 2.69x10
-3
 -0.0071 0.0024 2.97x10
-3
 5.64x10
-4
 
rs6986444 8 121695275 SNTB1 -3.321 (1.005) 9.77x10
-4
 0.0097 (0.0037) 8.27x10
-3
 0.0097 0.0037 9.07x10
-3
 3.28x10
-2
 
rs1158167 20 23526189 
CST3_CST9 
regions 
-2.059 (0.709) 3.74x10
-3
 -0.0687 (0.0026)   3.43x10
-150
 -0.0687 0.0026   9.91x10
-154
 2.23x10
-142
 
CKD 
rs775291 18 8775897 KIAA0802 -3.16 (0.8682) 2.81x10
-4
 0.1283 (0.0489) 8.65x10
-3
 0.1179 0.0488 1.57x10
-2
 3.84x10
-2
 
rs2536067 7 151056382 PRKAG2 2.121 (0.5949) 3.75x10
-4
 0.0684 (0.0206) 9.20x10
-4
 0.0658 0.0206 1.40x10
-3
 5.74x10
-3
 
 
 
 
 
 
Table 19: Meta-analysis between SNPs with a p-value ≤ 10
-3
 both in the Hypergenes Discovery Analysis and in CKDGen Consortium analysis 
(Pattaro C. et al. Genome-wide association and functional follow-up reveals new loci for kidney function. PLoS Genet. 2012; 8(3):e1002584). 
 
 
 
Marker Name Chr Position Gene BETA_disc (SE) P_disc 
BETA_CKDGen 
P_CKDGen 
BETA 
(combined) 
SE 
(combined) 
Inverse variance weighted P 
(combined) 
Z-scorx10 P 
(combinx10d) (SE) 
eGFR Creatinine 
rs2536067 7 151056382 PRKAG2 2.121 (0.595) 
3.75X10
-
4
 
-0.0063 (0.0013) 5.90X10
-7
 -0.0063 0.0013 1.21X10
-6
 4.81X10
-8
 
rs7312284 12 74403903 LOC390345 -2.274 (0.655) 
5.33X10
-
4
 
-0.0054 (0.0014) 1.07X10
-4
 -0.0054 0.0014 1.18X10
-4
 8.68X10
-4
 
rs17809619 3 20715647 LOC728976 -3.449 (0.989) 
4.99X10
-
4
 
0.0079 (0.0021) 1.92X10
-4
 0.0079 0.0021 1.74X10
-4
 1.45X10
-3
 
1.74X10
-
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4.3. Analysis Results: Candidate Gene approach 
We also performed a candidate gene approach looking for genes traditionally studied in 
cardiovascular diseases and renal function studies. To follow this approach we set a cut 
off of 10
-5
 in the Discovery analysis and 10
-3
 in the 15K analysis and identified several SNPs 
that mapped in genes already reported as associated to cardiovascular and renal 
pathways (see table 20). Two of them, NEDD4L and ABCA1, are suggestive of significance 
in all four studies even if the SNPs are different among the studies. The associated 
markers in NEDD4L and ABCA1 had a p-value < 10
-4
 in the Discovery dataset and p-value   
< 10
-2
 in the Validation and Population based study (table 21). According to the number of 
SNPs analyzed in NEDD4L gene, Bonferroni’s threshold was 2x10
-4
 in the Discovery and 
1x10
-3
 in the Validation, Cross sectional and Longitudinal analyses.  On the contrary, for 
ABCA1 gene, the significance threshold was 1.93x10
-4
 in the Discovery and 2.17x10
-3
 in the 
Validation, Cross sectional and Longitudinal analyses.  
NEDD4L is a regulator of the amiloride-sensitive epithelial sodium channel (ENaC) and is a 
candidate gene for salt sensitivity. ABCA1 is involved in lipid secretory pathways and 
especially in the co-transport of cholesterol and phospholipids and has been associated to 
cardiac diseases, hypertension and renal failure. Figures 11 and 12 show the regional plot 
for the two genes, considering all the SNPS analyzed in the Discovery, Validation, Cross 
sectional and Longitudinal studies, highlighted with different forms. For markers identified 
in more than one study, best p-value is reported. 
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SNP GENE 
EFFECT 
ALLELE 
BETA SE P CHR BP POSITION 
DISTANCE 
TO GENE 
RELATED PATHWAY 
Discovery Hypergenes 
rs6973843 PBEF1 A -4.213 1.003 2.82X10-5 7 105773180 flanking_5UTR -60587 
Atherosclerosis, Renal, 
Cardiovascular and Coronary artery 
diseases,  
Metabolic disorder 
rs1893468 NEDD4L A 3.451 0.8667 7.16X10-5 18 53769609 flanking_5UTR -93169 
Essential Hypertension,  
Salt sensitivity, Renin activity 
rs1539932 NEDD4L G 2.799 0.7153 9.52X10-5 18 53761811 flanking_5UTR -100967 
Validation Hypergenes 
rs10991411 ABCA1 G 4.749 1.619 3.43X10-3 9 106724097 intron -5940 
Atherosclerosis, Ischemia, Heart and 
Coronary artery disease, 
Hyperlipidemia 
rs6136 SELP C -3.666 1.397 8.80X10-3 1 167830575 coding [21/164] 
Nephropathy, Heart disease, 
Ischemic stroke,  
Essential hypertension 
rs9649847 EGFR A -3.011 1.158 9.42X10-3 7 55154632 intron -22841 Polycystic kidney disease 
rs10439056 NEDD4L A 4.742 1.835 9.88X10-3 18 53875962 intron -13024 
Essential Hypertension, Salt 
sensitivity, Renin activity 
Cross-sectional 
rs5767743 PPARA G 2.263 0.574 7.96X10-5 22 45000658 intron -3634 
Coronary Heart Disease, Type II 
diabetes, Plasma Lipid Levels, 
Hypertension, Atherosclerosis, 
Metabolic syndrome,  
Cardiac growth rs5766743 PPARA G 1.777 0.533 8.60X10
-4 22 44986042 intron -3692 
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SNP GENE 
EFFECT 
ALLELE 
BETA SE P CHR BP POSITION 
DISTANCE 
TO GENE 
RELATED PATHWAY 
rs5742912 SCNN1A G 5.247 1.666 1.63X10-3 12 6328611 coding [20/37] Blood pressure 
rs11888123 SLC8A1 A 1.547 0.505 2.17X10-3 2 40408981 intron -100136 Hypertension 
rs3794764 NOS2A A -1.634 0.551 2.98X10-3 17 23135555 intron -1296 
Atherosclerosis, Nephropathy, 
Microalbuminuria 
rs11854914 FBN1 A -2.434 0.849 4.16X10-3 15 46590506 intron -848 
Coronary artery disease,  
Aortic stiffness 
rs4253711 PPARA A 1.579 0.571 5.69x10-3 22 44973697 intron -545 
Coronary Heart Disease, Type II 
diabetes, Plasma Lipid Levels, 
Hypertension, Atherosclerosis, 
Metabolic syndrome,  
Cardiac growth 
rs10478694 EDN1 I 1.378 0.516 7.58x10-3 6 12398718 5UTR [73/130] 
Kidney dysfunction,  
Left ventricular hypertrophy,  
Blood pressure, Cardiac plasma 
endothelin-1 levels,  
Cholesterol plasma levels 
rs3771426 ADD2 G 1.751 0.660 7.99x10-3 2 70811011 intron -17187 Hypertension 
rs708498 PTGER2 A -1.751 0.671 9.07x10-3 14 51862250 intron -1439 
Myocardial infarct,  
Stroke ischemic 
rs6566955 NEDD4L G -1.338 0.515 9.35x10-3 18 54073769 intron -3503 
Essential Hypertension, Salt 
sensitivity, Renin activity 
Longitudinal 
rs3890733 VDR A -1.842 0.534 5.94x10-4 12 46575640 intron -4247 
Chronic renal failure related to 
vitamine D deficiency 
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SNP GENE 
EFFECT 
ALLELE 
BETA SE P CHR BP POSITION 
DISTANCE 
TO GENE 
RELATED PATHWAY 
rs12309274 WNK1 C 2.478 0.752 1.04x10-3 12 846209 intron -4483 Essential Hypertension 
rs6028 F5 G -1.816 0.594 2.33x10-3 1 167818306 coding [13/78] Cerebrovascular disease 
rs3917750 SELP A -1.740 0.569 2.34x10-3 1 167843377 intron -381 
Nephropathy, Heart disease, 
Ischemic stroke,  
Essential hypertension 
rs1800779 NOS3 G -1.721 0.563 2.34x10-3 7 150320876 intron -898 
Coronary Heart Disease, Chronic 
renal failure, Hypertension 
rs5517 KLK1 G -1.736 0.578 2.80x10-3 19 56015044 coding [77/59] Hypertension, Chronic renal failure 
rs1800783 NOS3 T -1.684 0.561 2.81x10-3 7 150320330 intron -1009 
Coronary Heart Disease, Chronic 
renal failure, Hypertension 
rs6951150 NOS3 A -1.648 0.563 3.60x10-3 7 150312847 flanking_5UTR -6233 
rs9804992 WNK1 A 2.160 0.754 4.34x10-3 12 859155 coding [155/303] Essential Hypertension 
rs760694 SELP C -1.576 0.555 4.70x10-3 1 167835322 intron -2284 
Nephropathy, Heart disease, 
Ischemic stroke,  
Essential hypertension 
rs2066715 ABCA1 A -2.985 1.092 6.52x10-3 9 106627854 coding [69/135] 
Atherosclerosis, Ischemia, Heart and 
Coronary artery disease, 
Hyperlipidemia 
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SNP GENE 
EFFECT 
ALLELE 
BETA SE P CHR BP POSITION 
DISTANCE 
TO GENE 
RELATED PATHWAY 
rs12445698 SLC12A3 A -1.794 0.670 7.69x10-3 16 55485717 intron -227 
Diabetic nephropathies, Renal 
disease, Essential hypertension, 
Pseudohypoaldosteronism, 
Hyperaldosteronism 
rs3212833 KLK1 A -1.592 0.595 7.75x10-3 19 56014691 intron -274 Hypertension, Chronic renal failure 
rs2241054 EGFR A -1.665 0.589 4.91x10-3 7 55207473 intron -697 Polycystic kidney disease 
rs3818109 SYNE1 G 1.445 0.540 7.77x10-3 6 152498168 intron -108 Renal Failure 
 
 
 
 
 
Table 20: SNPs with a p-value ≤ 10
-5
 in the Hypergenes Discovery and with a p-value ≤ 10
-3
 in the Validation, Cross Sectional and 
Longitudinal studies found related to Renal or Cardiovascular pathways. 
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CHR SNP BETA SE P GENE  POSITION  
DISTANCE TO 
GENE 
Discovery 
18 rs1893468 3.451 0.867 7.16X10
-5
 NEDD4L flanking_5UTR -93169 
18 rs1539932 2.799 0.715 9.52X10
-5
 NEDD4L flanking_5UTR -100967 
9 rs4149286 4.650 1.404 9.44X10
-4
 ABCA1 intron -1722 
Validation 
18 rs10439056 4.742 1.835 9.879X10
-3
 NEDD4L intron -13024 
9 rs10991411 4.749 1.619 3.427X10
-3
 ABCA1 intron -5940 
Cross sectional 
18 rs6566955 -1.338 0.515 9.350X10
-3
 NEDD4L intron -3503 
9 rs2230808 -1.102 0.549 4.468X10
-2
 ABCA1 coding [13/61] 
Longitudinal 
18 rs17064378 1.242 0.531 1.987X10
-2
 NEDD4L intron -46661 
9 rs2066715 -2.985 1.092 6.518X10
-3
 ABCA1 coding [69/135] 
 
 
 
 
Table 21: Analysis results in the four studies for different SNPs localized in NEDD4L and ABCA1. 
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Figure 11: Regional association plot for NEDD4L gene in the four 
studies. Degree of association is expressed on the left. 
Recombination rate is expressed on the right. 
 
Figure 12: Regional association plot for ABCA1 gene in the four studies. 
Degree of association is expressed on the left. Recombination rate is 
expressed on the right. 
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5. DISCUSSION 
The present study is part of HYPERGENES Project (European Network for Genetic-
Epidemiological Studies: building a method to dissect complex genetic traits using 
essential hypertension as a disease model) focused on the definition of a comprehensive 
genetic-epidemiological model of complex traits like essential hypertension and of 
intermediate phenotypes related to hypertension. Among the intermediate phenotypes 
available, in the present study we focused on eGFR as index of renal function.  
A strong relationship has been reported between renal dysfunction, hypertension and 
cardiovascular diseases; hypertension is present in more than 80% of patients with 
chronic kidney disease and contributes to progression of renal disease toward end stage 
as well as to cardiovascular events. Being renal function strongly related to blood pressure 
control and physiopathology of hypertension, the aim of this work was to identify genetic 
loci associated with renal function, in subjects affected by essential hypertension and in a 
population based study.  
CKD affects about 10% of the general population and causes significant morbidity and 
mortality. Apart from the risk conferred by traditional cardiovascular risk factors, there is 
a strong genetic component. Moreover heritability of GFR has been estimated to range 
from 36 to 75% [27]. Being the genetic component of GFR quite consistent, we performed 
a GWA study. In GWAs a large number of SNPs distributed in the genome are 
characterized in large numbers of individuals, with the aim to identify variants with a low 
or moderate effect on the phenotype of interest. To address this issue the precise 
characterization of the phenotype is crucial and inaccurate results can be the 
consequence of a poorly defined phenotype. 
The strength of our GWA study is based on sample selection: the hypertensive individuals 
have been very carefully selected for different phenotypes related to blood pressure 
control and renal function; the population based sample belongs to an extensively 
characterized and followed up cohort. This accurate selection lead the sample size to be 
small compared to other published studies, but decreases the bias of combining cohorts 
recruited with different criteria. On the other hand, the limited sample size can be the 
cause of the lack of validation of the findings in the different association studies 
performed. 
In the Discovery hypertensive dataset, two new loci were identified, rs4678878 and 
rs11129714, reaching a p-value of 3.83x10
-8
, above the genome-wide significance, and 
3.74x10
-7
 respectively. In both SNPs, the homozygosity for the risk allele G causes a mean 
eGFR value decrease of 8 ml/min/1.73 m
2 
(p-value < 10
-7
) compared to the AA genotype. 
The two SNPs mapped in STAC gene. These SNPs were not replicated in our further 
studies as associated to renal function or hypertension. This can be probably due to the 
small sample size and to the lack of markers mapping in STAC genes in the custom chip 
used to analyze the HYPERGENES Validation sample and the Population based study. The 
custom chip (including about 15,000 SNPs) has been created on the basis of the results 
obtained in the case-control Discovery of HYPERGENES. Moreover this chip has been built 
to interrogate candidate SNPs historically studied in hypertension field and SNPs involved 
in relevant pathways related to blood pressure control. Rs4678878 was the only SNP in 
STAC present on the chip and was not validated in any of the three studies performed. All 
best STAC SNPs identified in the discovery analysis were in linkage disequilibrium, with a 
D' ranging from 1 to 0.638. Nevertheless the associated p-values, ranging from 3.83x10
-8
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(rs4678878) to 8.14x10
-3
 (rs11921700), were not consistent with this finding. This can be 
explained by the R
2
 between rs4678878 and the other 15 best STAC SNPs, ranging from 
0.783 to 0.041. These markers are all located just before a hot spot of recombination and 
they could tag a causal SNP towards the 5’ of the gene. 
STAC gene encodes for a protein that consists of two well characterized domains: a 
cysteine-rich domain (CRD) of the protein kinase C (PKC) family and a Src homology 3 
(SH3) domain, both of them are frequently found in proteins involved in signal 
transduction. In tissue-expression patterns, the STAC mRNA was expressed predominantly 
in brain, although weak signals were detected in heart, liver, lung and kidney. The 
function of STAC is now under investigation. However, the primary structure consisting of 
domains important in signal transduction and its neuron specific expression pattern 
suggest that STAC plays a crucial role in neuron specific signal transduction pathways [59].  
Legha and colleagues (2010) identify STAC1 and STAC2 gene to define discrete and distinct 
subsets of dorsal root ganglia (DRG) neurons. They found that STAC1 mainly marks 
peptidergic nociceptive neurons, while STAC2 is principally expressed in a subset of 
nonpeptidergic nociceptors, in all trkB+ neurons and in a subpopulation of proprioceptive 
neurons [60].  
In the analysis performed using the 15K chip none of the SNPs analyzed reached the 
significance Bonferroni threshold of 10
-6
. However, in the Population based Cross 
sectional study, two findings, rs5767743 and rs5766743, with p-values of 7.96x10
-5
 and 
8.60x10
-4
 respectively, mapped in PPARA gene that has been described as involved in 
hypertension onset and progression. Peroxisome proliferator-activated receptors (PPARs) 
are members of a large family of ligand-inducible transcription factors that include 
receptors for retinoids and vitamin D, thyroid, and steroid hormones. PPARs regulate the 
expression of target genes by binding to DNA sequence elements, named PPAR response 
elements (PPRE). PPREs have been identified in the regulatory regions of a variety of 
genes involved in lipid and energy balance. 
Three different PPAR genes have been identified (α, δ, and γ). PPARA, maps in 
chromosome 22, position 22q13.31. It is mainly expressed in tissues that have a high ratio 
of fatty acid (FA) oxidation such as liver, kidney, heart and muscle. Numerous studies have 
demonstrated that several genes encoding enzymes involved in FA oxidation are 
modulated by PPARA. In addition to its role in FA oxidation, PPARA mediates the action of 
hypolipidemic drugs of the fibrate class on lipid and lipoprotein metabolism, it alters the 
synthesis of lipoprotein lipase and regulates the transcription of apolipoprotein C-III and 
other lipid-related genes. Fatty acids are essential biological components, used as 
metabolic fuels, covalent regulators of signaling molecules and essential components of 
cellular membranes. Altered levels of FA are linked to a variety of metabolic diseases 
including atherosclerosis, hyperlipidemia, obesity, insulin resistance, and type 2 diabetes. 
The finding that PPARA modulates gene expression of enzymes controlling FA oxidation 
suggests that it may be a candidate gene for type 2 diabetes and dyslipidemia. Moreover, 
Vohl and colleagues (2000) demonstrated that the heterozygosity for the L162V mutation 
in PPARA is unlikely to be a major risk factor for the development of type 2 diabetes but is 
associated with increased plasma apolipoprotein B levels [61]. Jamshidi et al (2002) 
showed how PPARA regulates left ventricular growth in response to exercise and 
hypertension stimuli and illustrated the important role of cardiac fatty acid metabolism in 
cardiac growth using the previously described functional L162V variant and a novel G/C 
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polymorphism in intron 7 of the human PPARA gene. These data may have therapeutic 
implications for patients with left ventricular hypertrophy (LVH) [62].  
We also performed a meta-analysis between our Discovery findings and the CKDGen 
Consortium meta-analysis, setting a p-value cut off of 10
-3
 in both dataset. We used the 
CKDGen results obtained from three different phenotypes of renal function: eGFR 
calculated from serum creatinine, eGFR calculated from cystatin C and incidence of 
chronic kidney disease. Since the three phenotypes describe renal function, a finding 
associated to more than one phenotype would be more relevant and informative from a 
physiological point of view. CKDGen meta-analysis provides association data from 67,093 
individuals, with a further replication in an independent sample of 22,982, reaching very 
high p-values. We could therefore confirm some of our findings. However, due to the 
different sample sizes, the results are strongly steered by CKDGen meta-analysis results.  
Rs17751897 (risk allele G), rs12625716 (risk allele A) and rs1158167 (risk allele G), having 
in our sample a p-value of 6.24x10
-4
, 8.36x10
-4
 and 3.74x10
-3
 respectively, reached an 
inverse variant weighted p-value of 1.83x10
-148
, 6.91x10
-149
 and 9.91x10
-154
 respectively in 
the meta-analysis with CKDGen data. The three markers map in the CST3-CST9 region, 
repeatedly associated with eGFR estimated from cystatin c; in all of them the homozygous 
for the risk allele cause a significant decrease in mean eGFR of around 4 ml/min/1.73 m
2 
(pvalue < 0.05) compared to the no-risk genotype. The cystatin superfamily consists of a 
large group of cystatin domain-containing proteins, most of which are reversible and 
tight-binding inhibitors of cysteine proteases. On the basis of the sequence similarity, 
presence or lack of disulfide bonds and physiological localization, this superfamily has 
been divided into three families: family I or stefins, family II or cystatins and family III or 
kininogens [63]. All of the characterized cystatins exhibit sequence homologies [64]. The 
cystatin locus on chromosome 20 contains the majority of the type 2 cystatin genes and 
pseudogenes.  
CST3 gene is located in chromosome 20, locus 20p11.21 and encodes for cystatin C 
protein, the most abundant extracellular inhibitor of cysteine proteases; the protein is 
found in high concentrations in all biological fluids, such as the cerebrospinal fluid and 
plasma and it is highest expressed in the epididymis, vas deferens, brain, thymus, and 
ovary. Cystatin C is mainly used as a biomarker of kidney function [31, 32, 36]. It is a 
cationic, low-molecular-weight protein (13 kD) freely filtered by the glomerulus and 
almost completely reabsorbed and catabolized by proximal tubular epithelial cells. It is not 
secreted by the tubule, it’s completely absent in urine and it is therefore measured only in 
plasma. It is produced at a constant rate by all cells and is not related to weight, age, sex 
and race. Several studies have reported significantly higher performance of cystatin C in 
estimating glomerular filtration rate [65]. 
Defects in CST3 are the cause of amyloidosis type 6 (AMYL6), a hereditary generalized 
amyloidosis due to cystatin C amyloid deposition. Amyloid deposition in the cerebral 
vessels results in cerebral amyloid angiopathy, cerebral hemorrhage and premature 
stroke. Cystatin C levels in the cerebrospinal fluid are abnormally low. Genetic variations 
in CST3 are also associated with age-related macular degeneration type 11 (ARMD11), a 
multifactorial eye disease representing the most common cause of irreversible vision loss 
in industrialized countries. It also seems to play a role in Alzheimer's disease. Recently, 
CST3 gene has been studied for its role in predicting new-onset or deteriorating 
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cardiovascular disease, as its expression is severely reduced in both atherosclerotic and 
aneurysmal aortic lesions [66, 67, 63].  
CST9 gene (testatin gene) is located in chromosome 20, locus 20p11.21. This gene belongs 
to a subgroup within the family 2 cystatins of cysteine protease inhibitors, together with 
cystatin T gene and cystatin-related epididymal spermatogenic (CRES) gene. Töhönen 
(1998) described testatin as expressed during testis cord formation in pre-Sertoli cells. 
Therefore, this gene may be involved in early testis development pathways [68]. 
Furthermore it may play a role in hematopoietic differentiation or inflammation [66].  
In the meta-analysis Rs2536067, with a p-value of 3.75x10
-4
 in the discovery sample, 
reached an inverse variant weighted p-value of 1.21x10
-6
 and a z-score p-value of 4.81x10
-
8
 in the meta-analysis on eGFR measured from serum creatinine. It maps to gene PRKAG2, 
encoding for the enzyme 5'-AMP-activated protein kinase (AMPK) subunit gamma-2. 
AMPKs are heterotrimeric proteins composed of a catalytic alpha subunit and two beta 
and gamma regulatory subunits. They are widely expressed in human tissues. They act as 
major regulators of cellular ATP levels and protect cells against stresses that cause ATP 
depletion. Although AMPKs are abundantly expressed in the kidney, their role in renal 
physiology is less clear than in other organs. In recent years various studies described 
roles for AMPKs in multiple aspects of renal physiology and disease including ion 
transport, podocyte function, renal hypertrophy, ischemia, inflammation, diabetes and 
polycystic kidney disease. 
PRKAG2 human gene maps to chromosome 7q36.1 and is composed of 16 exons. It 
encodes for a protein with four cystathionine beta-synthase domains. 
PRKAG2 protein plays a key role in regulating cellular energy metabolism in response to 
reduction of intracellular ATP levels. Mutations in this gene have been associated with 
ventricular pre-excitation (Wolff-Parkinson-White syndrome), a progressive conduction 
system disease, associated to cardiac hypertrophy. Defects in PRKAG2 are the cause of 
two congenital heart diseases: cardiomyopathy familial hypertrophic type 6 (CMH6), a 
hereditary heart disorder characterized by ventricular hypertrophy, which is usually 
asymmetric and often involves the interventricular septum, and glycogen storage disease 
of heart lethal congenital (GSDH), a glycogen storage diseases with clinically prominent 
cardiac involvement. Kottgen and colleagues (2010) identified rs7805747 in PRKAG2 as 
associated with renal function in CKDGen discovery analyses for both eGFRcrea and CKD 
phenotypes. The A allele of the SNP is associated with reduced glomerular filtration rate 
and thus a slightly increased risk for CKD [13, 32, 58].  
Through a candidate gene approach we could identify two genes, NEDD4L and ABCA1, 
suggestive of significance in all four analyses performed in our datasets (HYPERGENES 
Discovery and Validation studies and the two population based studies). 
NEDD4L reached the candidate gene’s Bonferroni threshold of 2.53x10
-4
 in the Discovery 
association study, while none of the SNPs analyzed using the 15K chip could reach a p-
value < 1.09x10
-3
. As showed in the regional plot (fig. 11), the best SNPs, rs1893468 and 
rs1539932, (p-value of 7.16x10
-5
 and 9.52x10
-5
 respectively) are located in the 5’-UTR 
flanking region of the gene. NEDD4L gene is located in chromosome 18, locus 18q21.31 
and encodes for the NEDD4L enzyme (neural precursor cell expressed developmentally 
down-regulated 4-like). The majority of rare monogenic forms of human hypertension 
identified are caused by mutations that directly or indirectly increase activity or 
expression of the amiloride-sensitive epithelial Na
+
 channel (ENaC) in the distal nephron. 
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This results in enhanced renal sodium reabsorption and salt-sensitive hypertension with 
compensatory low levels of plasma renin. NEDD4L protein acts as a channel remover of 
ENaC. Given the central role for ENaC in monogenic hypertension, the search for more 
common genetic variation in pathways controlling ENaC expression is an attractive 
approach for identification of essential hypertension susceptibility genes, as a 
complement to genome-wide association studies (GWAS) [69]. Manunta et al (2008) 
showed a consistent combined effect on renal sodium handling and blood pressure 
response of the NEDD4L (rs4149601 G/A), ADD1 (Gly460Trp) and WNK1 (rs880054 A/G) 
polymorphisms. NEDD4L rs4149601 A allele, at the first nucleotide of exon 1, leads to an 
alternative splice site which generates a isoform of NEDD4L downregulating ENaC more 
potently than the wild form of NEDD4L (rs4149601-G), suggesting that carriers of the G 
allele have higher ENaC expression and higher renal sodium reabsorption through ENaC 
than carriers of the A allele [70]. Jin and colleagues (2010) further identified several SNPs 
in NEDD4L gene that were linked to blood pressure regulation and hypertension. None of 
these was significantly validated in our analysis [71].  
The other gene identified through a candidate gene approach, ABCA1, did not exceed the 
candidate gene’s Bonferroni threshold of 1.93x10
-4
 in the Discovery phase and of 2.17x10
-
3
 in the analysis performed using the 15K chip. The top SNPs identified in this gene show 
high linkage disequilibrium and are located in a high recombination region (fig. 12). ABCA1 
map to chromosome 9q31.1 and it is composed of 50 exons. It encodes for ABCA1 
membrane protein, belonging to the adenosine triphosphate-binding cassette family, a 
group of proteins located in different tissues where they translocate different substrates 
to various compartment. It is implicated in co-transporting of cholesterol and 
phospholipids across plasma membrane, in intracellular lipids transport and transfer to 
apoA-1 e apoE, in the process of HDL particles formation, in electroneutral anion 
transport, in secretion of peptides like IL-1ß, and in engulfment of apoptotic cells by 
macrophages. It is expressed on cell surface, Golgi membranes and endolysosomal 
compartments of various tissues involved in the turnover of lipids such as the liver, the 
small intestine and adipose tissue, and in other tissue such as macrophages, lung, testis, 
pregnant uterus and placenta [72]. Among members of ABC family, several have been 
linked to inherited diseases, such as severe familial HDL deficiency, atherosclerotic 
complications and increased risk of myocardial infarction independent of HDL cholesterol 
levels [73].  
A correlation has been demonstrated between ABCA1 and proteins coded by genes SNTB1 
and VLDLR. Beta 1-syntrophin (SNTB1) was identified in our study in the meta-analysis 
with CKDGen data (rs6986444, p-value 9.77x10
-4
); it regulates the cellular distribution and 
activity of ABCA1 [74].  Very low-density lipoprotein receptor, VLDLR, one of our meta-
analysis findings (rs6475827, p-value 5.66x10
-4
), regulates expression of ABCA1 and 
cholesterol efflux [75].  
In conclusion our study identified a potential novel variant associated with hypertension 
and renal function in STAC gene (rs4678878, p-value of 3.83x10
-8
); this gene is likely 
involved in a neuron-specific signal transduction, although its function is not yet 
completely clear. The finding we obtained in STAC gene needs further investigation for 
different reasons: 1. We could validate only one SNP with the custom chip. Therefore it is 
necessary to fine map the region with a denser number of markers. This step could be 
followed by a validation in a larger sample. 2. STAC gene is implicated in neuronal 
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transduction and from a functional point of view this finding is not easy to explain in 
relation to the renal phenotype we are studying.  
Finally we could also identify some variants, mapping in loci already known as associated 
to renal function, in an accurately selected population (PPARA, CST3-CST9 region, 
PRKAG2, ABCA1, NEDD4L). 
The identification of genetic variants that can affect renal function may lead to a better 
understanding not only of GFR variability in the general population but also of the 
pathophysiology of CKD and progressive kidney function decline. Ultimately, this could 
lead to novel tools for diagnosis, prevention and therapy of CKD. 
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